<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Life (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Life (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2582</journal-id><journal-id journal-id-type="pmc-domain">life</journal-id><journal-id journal-id-type="publisher-id">life</journal-id><journal-title-group><journal-title>Life</journal-title></journal-title-group><issn pub-type="epub">2075-1729</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9506058</article-id><article-id pub-id-type="pmcid-ver">PMC9506058.1</article-id><article-id pub-id-type="pmcaid">9506058</article-id><article-id pub-id-type="pmcaiid">9506058</article-id><article-id pub-id-type="pmid">36143476</article-id><article-id pub-id-type="doi">10.3390/life12091440</article-id><article-id pub-id-type="publisher-id">life-12-01440</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Immune System as a Therapeutic Target for Alzheimer&#8217;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zieneldien</surname><given-names initials="T">Tarek</given-names></name><xref rid="af1-life-12-01440" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="J">Janice</given-names></name><xref rid="af1-life-12-01440" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sawmiller</surname><given-names initials="D">Darrell</given-names></name><xref rid="af2-life-12-01440" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="C">Chuanhai</given-names></name><xref rid="af1-life-12-01440" ref-type="aff">1</xref><xref rid="af3-life-12-01440" ref-type="aff">3</xref><xref rid="c1-life-12-01440" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cacabelos</surname><given-names initials="R">Ram&#243;n</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-life-12-01440"><label>1</label>Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA</aff><aff id="af2-life-12-01440"><label>2</label>MegaNano BioTech, Inc., 3802 Spectrum Blvd. Suite 122, Tampa, FL 33612, USA</aff><aff id="af3-life-12-01440"><label>3</label>USF-Health Byrd Alzheimer&#8217;s Institute, University of South Florida, Tampa, FL 33613, USA</aff><author-notes><corresp id="c1-life-12-01440"><label>*</label>Correspondence: <email>ccao@usf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2022</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">417790</issue-id><elocation-id>1440</elocation-id><history><date date-type="received"><day>26</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>09</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>24</day><month>09</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-09-26 08:17:59.340"><day>26</day><month>09</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="life-12-01440.pdf"/><abstract><p>Alzheimer&#8217;s disease (AD) is a heterogeneous neurodegenerative disorder and is the most common cause of dementia. Furthermore, aging is considered the most critical risk factor for AD. However, despite the vast amount of research and resources allocated to the understanding and development of AD treatments, setbacks have been more prominent than successes. Recent studies have shown that there is an intricate connection between the immune and central nervous systems, which can be imbalanced and thereby mediate neuroinflammation and AD. Thus, this review examines this connection and how it can be altered with AD. Recent developments in active and passive immunotherapy for AD are also discussed as well as suggestions for improving these therapies moving forward.</p></abstract><kwd-group><kwd>immunotherapy</kwd><kwd>peripheral immune system</kwd><kwd>aging</kwd><kwd>microglia</kwd><kwd>Alzheimer&#8217;s disease</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-life-12-01440"><title>1. Introduction</title><p>AD is a neurodegenerative disorder initially described by Alois Alzheimer in 1906 [<xref rid="B1-life-12-01440" ref-type="bibr">1</xref>]. Currently, AD is the most common cause of dementia, and has an advancing global prevalence without any apparent cure [<xref rid="B2-life-12-01440" ref-type="bibr">2</xref>]. In general, AD is a heterogenous and multifactorial disease, with some of the major known pathological factors consisting of aggregated amyloid beta and phosphorylated tau. The accumulation of excess A&#946; aggregated into toxic fibrillar deposits in the brain has been implicated in dementia and neuronal degeneration via the disruption of synaptic and neuronal function [<xref rid="B3-life-12-01440" ref-type="bibr">3</xref>]. Furthermore, AD can be grouped into different subtypes based upon the pathological factors, with subjects differing in terms of gender distribution, age of onset, cognitive deterioration, and APOE genotype [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>]. Due to this, AD manifests itself as a multi-domain amnestic disorder, with different patients revealing variant syndromes [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>,<xref rid="B5-life-12-01440" ref-type="bibr">5</xref>]. Furthermore, aging appears to be the most critical factor for AD due to its considerable repercussions on the immune system [<xref rid="B6-life-12-01440" ref-type="bibr">6</xref>].</p><p>Despite our advancing knowledge of AD pathogenesis, there have been more than 200 unsuccessful clinical trials in the last decade [<xref rid="B7-life-12-01440" ref-type="bibr">7</xref>]. In general, this could be attributed to recruiting subjects with a high degree of heterogeneity, which might lead to inappropriate single protein targeting in such a multifactorial disease [<xref rid="B5-life-12-01440" ref-type="bibr">5</xref>,<xref rid="B7-life-12-01440" ref-type="bibr">7</xref>,<xref rid="B8-life-12-01440" ref-type="bibr">8</xref>]. In the present review, the effects of aging on the peripheral immune system are discussed, as well as recent advances in active and passive immunotherapies in an effort to rebalance the immune system of AD patients. Suggestions are also offered in the form of personalized medicine in an effort to find effective immunotherapies for AD treatment.</p></sec><sec id="sec2-life-12-01440"><title>2. Pathological Theories of AD</title><p>Alzheimer&#8217;s disease is characterized by the accumulation of amyloid-beta (A&#946;) formed by neuritic plaques and neurofibrillary tangles (NFTs) [<xref rid="B9-life-12-01440" ref-type="bibr">9</xref>]. The two components of neuropathological changes associated with AD include positive lesions due to the accumulation of deposits in the brain and negative lesions due to losses by atrophy resulting from neural and synaptic loss [<xref rid="B9-life-12-01440" ref-type="bibr">9</xref>]. The hallmark proteinopathies for AD include A&#946; and pathologic tau which serve as potential biomarkers for onset of AD [<xref rid="B10-life-12-01440" ref-type="bibr">10</xref>]. Studies have shown abnormal amyloid deposition can lead to rapid decline of cognition, progressive atrophy, and hypometabolism [<xref rid="B10-life-12-01440" ref-type="bibr">10</xref>].</p><p>Amyloid precursor protein (APP) is a type 1 membrane protein which plays a significant role in the development of AD with the proteolytic activity of &#946;- and &#947;-secretase complex [<xref rid="B11-life-12-01440" ref-type="bibr">11</xref>]. The two byproducts of APP metabolism that are generated in neurotoxic amyloid plaques consists of abnormally folded A&#946;40 and A&#946;42 [<xref rid="B11-life-12-01440" ref-type="bibr">11</xref>]. An imbalance between the production and clearance of these alternate forms can initiate AD pathogenesis. A&#946;42 experiences conformational changes, making it more prone to aggregation into oligomers due to the increased hydrophobic nature in the C-terminus, furthering the formation of fibrils, plaques, and phosphorylated tau. This results in neuritic dystrophy and furthers the spread of neurodegeneration [<xref rid="B12-life-12-01440" ref-type="bibr">12</xref>]. The oligomeric A&#946;42 is found in abundance around plaques, making oligomers the causative agent for neurodegeneration while also inducing tau hyperphosphorylation [<xref rid="B13-life-12-01440" ref-type="bibr">13</xref>]. It has been found in animal models that A&#946; oligomers impair memory, inhibit long-term potentiation, and decrease synapse density [<xref rid="B13-life-12-01440" ref-type="bibr">13</xref>]. As such, an approach to AD treatment has been to slow A&#946; peptide formation in the brain via the manipulation of &#947;- and &#946;-secretases (<xref rid="life-12-01440-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B14-life-12-01440" ref-type="bibr">14</xref>]. In general, immunotherapy targeting A&#946; has been prominently used in AD because the accumulation of A&#946; within the brain has been noted to be an early trigger [<xref rid="B15-life-12-01440" ref-type="bibr">15</xref>].</p><p>Tau pathology is another contributing factor in AD pathogenesis. The essential functions of tau proteins are to promote the interaction and stability of microtubules and tubulin in the neural network [<xref rid="B16-life-12-01440" ref-type="bibr">16</xref>]. In AD, however, tau mutations can occur inhibiting these vital functions [<xref rid="B17-life-12-01440" ref-type="bibr">17</xref>]. Seemingly interconnected in the formation of neuritic plaques are microglia, A&#946;, and tau, where the reaction between A&#946; and microglia results in tau accumulation [<xref rid="B18-life-12-01440" ref-type="bibr">18</xref>]. The main forms of tau that contribute to AD progression are misfolded, aggregated, and hyperphosphorylated forms which spread throughout the brain in a prion-like manner, inducing further aggregation through formation of paired helical filaments [<xref rid="B19-life-12-01440" ref-type="bibr">19</xref>]. The hyperphosphorylated tau proteins create neurofibrillary tangles that accumulate within axons and dendrites resulting in neuronal loss [<xref rid="B20-life-12-01440" ref-type="bibr">20</xref>]. Over time, the toxicity of tau is enhanced due to the alterations in the kinases or phosphatases that target tau, thereby suppressing and silencing many neurons [<xref rid="B21-life-12-01440" ref-type="bibr">21</xref>].</p><p>Genetics can influence the risk of developing AD, as seen with the association of the apolipoprotein E (APOE) genotype with AD [<xref rid="B22-life-12-01440" ref-type="bibr">22</xref>]. The variants of the APOE gene include &#949;2, &#949;3, and &#949;4 alleles, with the APOE &#949;4 isoform being a crucial genetic risk factor having significant detrimental effects in AD development [<xref rid="B23-life-12-01440" ref-type="bibr">23</xref>]. APOE &#949;4 has been associated with a lower age of onset and elevated prevalence of AD, with the clinical onset age being 68 years in APOE &#949;4 homozygotes and 76 years in APOE &#949;4 heterozygotes, compared to 84 years of age in non-&#949;4 carriers [<xref rid="B24-life-12-01440" ref-type="bibr">24</xref>,<xref rid="B25-life-12-01440" ref-type="bibr">25</xref>]. This increased risk is associated with the APOE &#949;4 allele inhibiting A&#946; clearance and advancing A&#946; aggregation [<xref rid="B26-life-12-01440" ref-type="bibr">26</xref>].</p></sec><sec id="sec3-life-12-01440"><title>3. Effects of Aging on AD</title><p>Aging is typically considered the most critical risk factor for AD and has extensive repercussions for the peripheral tissues and immune system [<xref rid="B27-life-12-01440" ref-type="bibr">27</xref>]. Aging has been determined to alter the constituents of innate immunity extending from the behavior of dendritic cells, natural killer cells, monocytes, and neutrophils, as well as the expression of the signaling molecules [<xref rid="B28-life-12-01440" ref-type="bibr">28</xref>]. This is crucial because innate immunity offers vast host protection via the detection of pathogen-associated molecular patterns (PAMPs) and the activation of signaling pathways that lead to the expeditious release of chemokines and cytokines, which are pivotal soluble molecules that serve as immune effectors [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Subsequently, inflammation is also witnessed with aging, and is distinguished by functional deterioration and incessant low-grade inflammation in aging individuals [<xref rid="B30-life-12-01440" ref-type="bibr">30</xref>]. The intracellular multicomponent sensors and receptors that allow for the release of the eminent pro-inflammatory cytokines IL-18 and IL-1&#946; are inflammasomes [<xref rid="B31-life-12-01440" ref-type="bibr">31</xref>,<xref rid="B32-life-12-01440" ref-type="bibr">32</xref>]. Consequently, the distinct inflammasome expression of gene modules in geriatric patients has been correlated with arterial stiffness, oxidative stress, high blood pressure, and metabolic impairment, thereby leading to reduced patient life spans [<xref rid="B33-life-12-01440" ref-type="bibr">33</xref>]. Correspondingly, the elevated levels of IL-18 circulating due to increased age show a significant decrease in mice that lack the Asc inflammasome adaptor or the Nlrp3 inflammasome [<xref rid="B34-life-12-01440" ref-type="bibr">34</xref>]. Nonetheless, a plethora of proinflammatory factors and cytokines have been correlated with age-related cognitive and physical deterioration, and some such as IL-6 have been utilized as markers of dysfunctional inflammatory responses [<xref rid="B35-life-12-01440" ref-type="bibr">35</xref>].</p><p>Aging also correlates with elevated cell transcriptional fluctuations and volatility, inclusive of hematopoietic cells [<xref rid="B36-life-12-01440" ref-type="bibr">36</xref>,<xref rid="B37-life-12-01440" ref-type="bibr">37</xref>,<xref rid="B38-life-12-01440" ref-type="bibr">38</xref>]. Proportionately, older cells from the peripheral immune system encompass epigenetic modifications that are eminently heterogenous when comparing differing individuals and even different cells, as shown by profiling of the single-cell chromatin modifications [<xref rid="B38-life-12-01440" ref-type="bibr">38</xref>]. Furthermore, considerable variances in the cell populations that arbitrate adaptive immunity have been witnessed in a variety of research studies, with a reduction in circulating B cells and na&#239;ve T cells being common, while T cells that are terminally differentiated seem to be found in elevated levels in geriatric subjects [<xref rid="B28-life-12-01440" ref-type="bibr">28</xref>,<xref rid="B39-life-12-01440" ref-type="bibr">39</xref>]. In general, this is attributed to the thymic involution that occurs with age and is mediated by the inflammasome Nlrp3, leading to a deficiency in T-cell homeostasis [<xref rid="B34-life-12-01440" ref-type="bibr">34</xref>]. Furthermore, aging has detrimental effects on na&#239;ve T cells since they tend to retain a more limited range of T-cell receptor repertoires, leading to debilitated virtual memory phenotypes, which are consorted with extensive epigenetic alterations [<xref rid="B38-life-12-01440" ref-type="bibr">38</xref>,<xref rid="B39-life-12-01440" ref-type="bibr">39</xref>,<xref rid="B40-life-12-01440" ref-type="bibr">40</xref>,<xref rid="B41-life-12-01440" ref-type="bibr">41</xref>]. Consequently, CD4+ and CD8+ T cells tend to exhibit characteristics reminiscent of cellular senescence as they become more aged [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>].</p><p>Aging results in an amassment of senescent cells since they enter a long-standing scheme of cell-cycle arrest that is elicited by a plethora of stressors [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Recently, research has demonstrated an intricate mechanism that is fundamental to cell biogenesis, as well as elucidated their actions in distinct pathology and physiology [<xref rid="B42-life-12-01440" ref-type="bibr">42</xref>,<xref rid="B43-life-12-01440" ref-type="bibr">43</xref>]. In host immunity, the engagement of senescent cells is intertwined to their attained capability of secreting pro-inflammatory cytokines, known as the senescence-associated secretory phenotype [<xref rid="B44-life-12-01440" ref-type="bibr">44</xref>]. The senescence-associated secretory phenotype is induced principally by oncogenic stress, NF-&#954;B in response to damaged DNA, and developmental cues, which initiates the IL-6, IL-8, IL1&#946;, and TNF-&#945; transcription [<xref rid="B45-life-12-01440" ref-type="bibr">45</xref>].</p><p>Consequent to inducing a pro-inflammatory phenotype, aging also diminishes molecules that are necessary for brain rejuvenation [<xref rid="B46-life-12-01440" ref-type="bibr">46</xref>]. To illustrate, when old mice collectively shared their circulation with younger mice via parabiosis, there appeared to be transmission of aging phenotypes to the brain and peripheral tissues of youthful mice, with the converse scenario also taking place [<xref rid="B47-life-12-01440" ref-type="bibr">47</xref>]. In fact, B2M and CCL11 immune factors have also been demonstrated to adversely influence memory and neurogenesis when enriched in the plasma of geriatric individuals [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>,<xref rid="B47-life-12-01440" ref-type="bibr">47</xref>]. However, the complementing of growth and differentiation factor 11 (GDF-11) to older mice has been demonstrated to benefit the heart and boost neurogenesis [<xref rid="B48-life-12-01440" ref-type="bibr">48</xref>]. Nevertheless, GDF-11 activity and expression is a contentious topic and subsequent research is crucial to corroborate its activity in the rejuvenation of the host. However, an almost full-fledged restoration of neuronal and synaptic proteins has been observed in elderly APP-expressing mice subsequent to exposing the mice to circulating juvenile blood or after obtaining a plasma transfusion [<xref rid="B49-life-12-01440" ref-type="bibr">49</xref>]. This resulted in enhanced associative and working memory after intravenous administration of the plasma of younger mice when there were no alterations in the amyloid load [<xref rid="B49-life-12-01440" ref-type="bibr">49</xref>]. Consequently, a profound exploration into factors that contribute to brain rejuvenation has allowed for the recognition of tissue inhibitor of metalloproteases 2 (TIMP2), which is found in the umbilical cord blood at greater amounts [<xref rid="B50-life-12-01440" ref-type="bibr">50</xref>]. TIMP2 is critical since it boosts neuronal plasticity in the brain via the possible modulation of the extracellular matrix, but it also influences hippocampal synaptic plasticity via the systemic circulation [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>].</p><p>A&#946; aggregation and deposition seems to increase with age, which could be associated with the pathological aggregation found in AD [<xref rid="B51-life-12-01440" ref-type="bibr">51</xref>]. In fact, it has been elucidated that exceptionally insoluble proteins from older <italic toggle="yes">Caenorhabditis elegans</italic> or mice brains could commence A&#946; aggregation in vitro, but this was not seen when younger subjects were utilized [<xref rid="B51-life-12-01440" ref-type="bibr">51</xref>]. Furthermore, insoluble A&#946; has also been shown to lead to neuronal stress, thereby increasing Tau-expression and phosphorylation, while also leading to microglia induced inflammation [<xref rid="B52-life-12-01440" ref-type="bibr">52</xref>]. Although tau pathology seems to be more strongly correlated with AD-related cognitive dysfunction than A&#946;, the A&#946; cascade is considered an earlier process, and early intervention preventing A&#946; aggregation could help immune dysfunction [<xref rid="B53-life-12-01440" ref-type="bibr">53</xref>].</p><sec id="sec3dot1-life-12-01440"><title>3.1. Effects of the Peripheral Immune Cells in Aging-Related Brain Homeostasis</title><p>In the parenchyma, microglial cells can be found, and a limited but significant quantity of NK cells, B cells, T cells, and dendritic cells roam to the choroid plexus and meninges to populate them [<xref rid="B54-life-12-01440" ref-type="bibr">54</xref>]. Various studies have determined that CD4+ T cells have an imperative role in preserving na&#239;ve mice behavioral and cognitive capacities [<xref rid="B55-life-12-01440" ref-type="bibr">55</xref>,<xref rid="B56-life-12-01440" ref-type="bibr">56</xref>]. Both T<sub>H</sub>1 (IFN-&#947; producing) and T<sub>H</sub>2 (IL-4-producing) CD4+ T cells populate the meninges in steady-state conditions [<xref rid="B57-life-12-01440" ref-type="bibr">57</xref>]. IFN&#947; assists crucial neuronal circuits that are utilized for social behaviors and IL-4 eases learning via the regulation of meningeal dendritic cells and the stimulation in astrocytes of BDNF expression [<xref rid="B57-life-12-01440" ref-type="bibr">57</xref>,<xref rid="B58-life-12-01440" ref-type="bibr">58</xref>]. As such, T cells and their secreted cytokines have crucial roles in maintaining homeostatic brain processes [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Nonetheless, aged choroid plexus in both mice and humans show strong IFN-I signaling, which has been demonstrated to counter the function of IFN&#947;, hinder hippocampal neurogenesis and cognitive functions, as well as disrupt monocyte infiltration [<xref rid="B59-life-12-01440" ref-type="bibr">59</xref>]. Therefore, aging potentially disrupts the balance of brain-homing peripheral immune cells, thereby negatively impacting crucial functions of the CNS [<xref rid="B59-life-12-01440" ref-type="bibr">59</xref>].</p><p>The choroid plexus is an epithelial tissue found within the brain&#8217;s ventricles [<xref rid="B60-life-12-01440" ref-type="bibr">60</xref>]. The choroid plexus forms the blood&#8211;CSF barrier and has a crucial role in preserving homeostasis of the brain by excreting neurotrophic factors into the CSF, participating in A&#946; clearance, and trafficking leukocytes [<xref rid="B60-life-12-01440" ref-type="bibr">60</xref>]. When observing na&#239;ve mice, it has been found that the stroma of the choroid plexus contain greater than 50% of CD4+ and CD8+ T cells in the brain [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. The majority of these T cells embody effector memory phenotypes&#8212;inclusive of T<sub>H</sub>1, T<sub>H</sub>2, and T<sub>regs</sub>&#8212;and have the ability of recognizing antigens in the CNS [<xref rid="B61-life-12-01440" ref-type="bibr">61</xref>]. Nonetheless, aged choroid plexus demonstrates a contorted T<sub>H</sub>1 to T<sub>H</sub>2 balance ratio, leading to elevated expression of the CCL11 chemokine, reduced permeability to leukocytes due to IL-4 and IFN&#947; differential impacts on the epithelial cells of the choroid plexus, and hindered cognition [<xref rid="B62-life-12-01440" ref-type="bibr">62</xref>]. Type I interferon (IFN-I) is a considerable innate immune cytokine frequently implicated in host defense and autoimmune circumstances [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Furthermore, the aged choroid plexus of both mice and human subjects exhibit compelling IFN-I signaling, which has been revealed to counterbalance the actions of IFN&#947;, disturb monocyte infiltration, and hinder neurogenesis of the hippocampus and cognitive function [<xref rid="B61-life-12-01440" ref-type="bibr">61</xref>]. Due to this, aging has been determined to disturb the balance of the peripheral immune cells in the brain, which have detrimental effects on the function of the CNS [<xref rid="B63-life-12-01440" ref-type="bibr">63</xref>].</p></sec><sec id="sec3dot2-life-12-01440"><title>3.2. The Innate Immune System</title><p>In AD pathology, observations into the brain can elucidate microglial differentiation into a novel form that is correlated with neurodegenerative diseases, encompassing modified molecular expression profiles, as well as constrained phagocytic capacities [<xref rid="B64-life-12-01440" ref-type="bibr">64</xref>]. Nonetheless, the definite source of the amoeboid senile plaque surrounding myeloid cells has been a topic of much discussion, due to the strenuous task of characterizing locally activated microglial cells with those infiltrating myeloid cells [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. However, contemporary studies have indicated that peripheral macrophages could retain an individualized transcriptional and functional identity in the CNS while engrafting the brain [<xref rid="B65-life-12-01440" ref-type="bibr">65</xref>]. Furthermore, infiltration of the peripheral myeloid cells has also been indicated to engage in the clearance of A&#946; [<xref rid="B66-life-12-01440" ref-type="bibr">66</xref>].</p><p>Unusual variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have also been observed to elevate AD development by at least twofold [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Consequently, TREM2-dependent phenotypes in mice model studies have shown that the phenotypes can elucidate the role of microglia and TREM2 in CNS injury, and thereby shed light on AD pathogenic neuroinflammation [<xref rid="B67-life-12-01440" ref-type="bibr">67</xref>]. Moreover, other than the upregulation within the CNS, TREM2 mRNA and protein also show elevated expression in the peripheral leukocytes of subjects with AD, which has been associated with atrophy of the hippocampus and cognitive deficits [<xref rid="B68-life-12-01440" ref-type="bibr">68</xref>,<xref rid="B69-life-12-01440" ref-type="bibr">69</xref>]. Nonetheless, it is uncertain whether increased expression of peripheral TREM2 indeed has an operative repercussion or if it resonates the continuous systemic inflammation observed in AD patients.</p><p>Neutrophils are the myeloid cells with the most abundance in the peripheral blood of humans [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Neutrophils have crucial roles in the innate immune system and are present in the brain parenchyma of 5xFAD and 3xTg-AD mice [<xref rid="B70-life-12-01440" ref-type="bibr">70</xref>]. In the brain parenchyma of these mice, it was noted that neutrophils seemed to boost cognitive decline, amyloid plaques, and tau tangles [<xref rid="B70-life-12-01440" ref-type="bibr">70</xref>]. However, further research revealed that treating 3xTg-AD mice for 10 months with TNF-&#945; modulator compounds yielded elevated infiltration of the brain by neutrophils, which concurred with decreased amyloid and tau pathologies and enhanced memory [<xref rid="B71-life-12-01440" ref-type="bibr">71</xref>]. As such, further research is necessary to elucidate the operative characteristics of infiltrating neutrophils in AD pathogenesis.</p></sec><sec id="sec3dot3-life-12-01440"><title>3.3. The Adaptive Immune System</title><p>The antibody production by B cells to amyloid beta has been extensively studied over the past two decades [<xref rid="B72-life-12-01440" ref-type="bibr">72</xref>]. In fact, immortalized B cells were initially discovered to secrete antibodies with specificity towards A&#946; peptides in the peripheral blood of subjects with AD [<xref rid="B72-life-12-01440" ref-type="bibr">72</xref>]. As of now, anti-A&#946; antibodies have been found to circulate at differing levels in human blood, regardless of AD diagnosis [<xref rid="B73-life-12-01440" ref-type="bibr">73</xref>,<xref rid="B74-life-12-01440" ref-type="bibr">74</xref>]. This led to the consideration of B-cell mediated immune responses as a therapeutic strategy, since studies have shown that A&#946; immunization has the potential of preventing the advancement of amyloid plaques, as well as gliosis and neuritic dystrophy in PDAPP mice [<xref rid="B75-life-12-01440" ref-type="bibr">75</xref>]. Nevertheless, as witnessed in the AN1792 clinical human trials, the development of encephalitis in approximately 6% of the subjects led to termination of the trials [<xref rid="B76-life-12-01440" ref-type="bibr">76</xref>]. In this case, the encephalitis was potentially traced to the T<sub>H</sub>1 response stimulation via active immunization [<xref rid="B76-life-12-01440" ref-type="bibr">76</xref>]. Consequential animal model research also indicated that antibody clones that are A&#946; -specific could ameliorate AD progression without the engagement of T cells, thereby encouraging passive immunotherapies in the clinical trials of AD subjects [<xref rid="B77-life-12-01440" ref-type="bibr">77</xref>]. Nonetheless, passive immunotherapy has shown varied results, and a plethora of clinical trials are still continuing [<xref rid="B78-life-12-01440" ref-type="bibr">78</xref>,<xref rid="B79-life-12-01440" ref-type="bibr">79</xref>].</p><p>Other than specific humoral responses to proteins correlated with the pathology of AD, the repertoire of peripheral immunoglobulin appears to be abnormally regulated [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. To illustrate, natural antibodies that are released by B cells devoid of exogenous invigoration are copious in human sera, commonly self- or poly-reactive, and effectuate crucial activity in the removing of cellular waste and targeting of pathogens [<xref rid="B80-life-12-01440" ref-type="bibr">80</xref>]. Consequently, the levels of natural IgG recognizing self-antigens has been shown to be affected by disease and age [<xref rid="B81-life-12-01440" ref-type="bibr">81</xref>]. When observing other neurodegenerative disorders, a significant decrease in autoantibodies was detected in AD, multiple sclerosis, and Parkinson&#8217;s disease (PD) patient sera [<xref rid="B81-life-12-01440" ref-type="bibr">81</xref>]. However, the inciting factor and operative significance of this reduction has not yet been elucidated. Nonetheless, antibody panels have been utilized as biomarkers, and some studies have demonstrated the ability to differentiate AD and MCI patients from age-matched controls [<xref rid="B82-life-12-01440" ref-type="bibr">82</xref>].</p><p>Subsequent studies have also provided additional intuitiveness on immunoglobulin&#8217;s role in AD [<xref rid="B83-life-12-01440" ref-type="bibr">83</xref>]. To illustrate, elevated levels of mice IgGs were observed in correlation with microglia in 5xFAD mice brains [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. Deficient in A&#946; specificity, the proteins were revealed to interact with the Fc receptor of microglia, leading to the activation of the signaling pathway and triggering the phagocytosis of A&#946;, which thereby results in reduced plaque loads [<xref rid="B29-life-12-01440" ref-type="bibr">29</xref>]. However, even though the study conducted by Marsh et al. did not examine the infiltrating IgG&#8217;s antigen specificities, the defensive effects of mice IgG are evocative of the favorable effect yielded by intravenous immunoglobulin administration [<xref rid="B83-life-12-01440" ref-type="bibr">83</xref>]. However, there have also been unfavorable reports documenting low-dose intravenous immunoglobulin administration in human clinical trials. In a Phase III trial conducted by Relkin et al., there were no beneficial effects observed for the two administered doses (0.2 and 0.4 g/kg every 2 weeks for 18 months), although the subjects with mild- to moderate-AD showed good tolerability of treatment [<xref rid="B84-life-12-01440" ref-type="bibr">84</xref>]. Even more, there were no difference between the placebo and intravenous immunoglobulin treated subjects in terms of the rate of occurrence of amyloid-related imaging abnormalities (ex., microhemorrhages or brain edema) [<xref rid="B84-life-12-01440" ref-type="bibr">84</xref>]. Nonetheless, the definitive subsets of IgGs that deliberate augmented neuroprotection warrant further research.</p><p>In terms of T cells, the brains of AD patients post-mortem have been found to have CD4+ and CD8+ T cells, periodically near microglia and neuritic plaques [<xref rid="B85-life-12-01440" ref-type="bibr">85</xref>,<xref rid="B86-life-12-01440" ref-type="bibr">86</xref>]. Likewise, elevated levels of T cells have been observed to infiltrate the parenchyma of various APP transgenic mice [<xref rid="B87-life-12-01440" ref-type="bibr">87</xref>]. To illustrate, Browne et al. demonstrated a significant portion of infiltrating T cells with ability to generate IL-17 and IFN&#947; in APP/PS1 brains [<xref rid="B87-life-12-01440" ref-type="bibr">87</xref>]. Nevertheless, other studies have revealed that infiltrating T cells continuously demonstrate an inactivated phenotype with decreased IFN&#947; producing abilities and a scarcity of local proliferation [<xref rid="B88-life-12-01440" ref-type="bibr">88</xref>]. Furthermore&#8212;in Tg2576, APP/PS1, and ArcA&#946; models of AD&#8212;they did not appear to co-localize with the amyloid plaques [<xref rid="B88-life-12-01440" ref-type="bibr">88</xref>].</p><p>Due to the distinct and critical activities of T helper subsets in various diseases, it would be crucial to disseminate how varying T<sub>H</sub> cell populations explicitly modulate AD. In APP/PS1 mice models, adoptive transfer of A&#946;-specific T<sub>H</sub>1 cells&#8212;although not T<sub>H</sub>2 or T<sub>H</sub>17 cells&#8212;led to exacerbated AD pathology, excessive microglial activation, and impaired cognitive function [<xref rid="B87-life-12-01440" ref-type="bibr">87</xref>]. The plaque clearing and pathogenic actions of T<sub>H</sub>1 cells were elucidated when after A&#946; vaccination, infiltration of A&#946;-specific IFN&#947; producing T cells occurred in the brains of J20 mice, thereby clearing plaques, but causing meningoencephalitis, mirroring the pathogenicity of AN1792 [<xref rid="B89-life-12-01440" ref-type="bibr">89</xref>]. Nevertheless, direct cerebrospinal injections of A&#946;-specific T<sub>H</sub>1 cells elevated neurogenesis and amyloid plaque clearance in the absence of autoimmunity, suggesting an additional impact of peripheral T<sub>H</sub>1 cells in the APP/PS1 mice models [<xref rid="B90-life-12-01440" ref-type="bibr">90</xref>]. In addition, the adoptive transfer of A&#946;-specific T<sub>H</sub>2 cells, while lacking evidence of brain infiltration, enhanced the working memory of APP/PS1 mice, in addition to minimized vascular amyloidosis and systemic inflammation [<xref rid="B91-life-12-01440" ref-type="bibr">91</xref>]. As such, A&#946;-specific T<sub>H</sub>1 and T<sub>H</sub>2 cells seem to alter the pathology of A&#946; in a plethora of differing ways.</p></sec><sec id="sec3dot4-life-12-01440"><title>3.4. Central-Peripheral Neuroimmune Crosstalk in AD</title><p>In vivo assessments of the CNS immune dysfunction in humans have been methodologically limited [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>]. However, numerous studies have demonstrated that upregulated CSF pro-inflammatory markers manifest in early AD, thereby leading to an inflammatory response in the CNS [<xref rid="B93-life-12-01440" ref-type="bibr">93</xref>,<xref rid="B94-life-12-01440" ref-type="bibr">94</xref>,<xref rid="B95-life-12-01440" ref-type="bibr">95</xref>]. In general, pathological and clinical correlations with the inflammatory response are varied and marker contingent, accentuating the fact that granular assessment of particular pathways are crucial at each stage of AD severity [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>]. To illustrate, various studies have demonstrated that elevated levels of CSF chemokine (C-C motif) ligand 2 (CCL2) envision expedited clinical deterioration in AD, particularly during pre-dementia stages [<xref rid="B94-life-12-01440" ref-type="bibr">94</xref>,<xref rid="B95-life-12-01440" ref-type="bibr">95</xref>]. On the other hand, other studies have indicated that elevated levels of soluble triggering receptor expressed on myeloid cells 2 (TREM2) and convergence of various anti-inflammatory and pro-inflammatory factors in CSF are predictive of a more gradual clinical deterioration in AD [<xref rid="B93-life-12-01440" ref-type="bibr">93</xref>,<xref rid="B96-life-12-01440" ref-type="bibr">96</xref>]. In fact, utilizing the National Institute on Aging&#8212;Alzheimer&#8217;s Association 2011 criteria allowed Meyer et al. to stratify subjects on the basis of preclinical biomarker stages, thereby leading to the discovery that CSF inflammation levels were decreased in stage 1 when compared to stage 0, but considerably higher in stage 2 [<xref rid="B97-life-12-01440" ref-type="bibr">97</xref>]. The four stages that participants were allocated into were defined as stage 0 (no abnormality), stage 1 (reduced amyloid-&#946;<sub>1-42</sub>), stage 2 (elevated total-tau and reduced amyloid-&#946;<sub>1-42</sub>), and &#8220;suspected non-AD pathology&#8221; [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>]. This unanticipated result suggests that immune marker activity could potentially diminish along with the earliest emergence of amyloid-&#946; plaque pathology [<xref rid="B97-life-12-01440" ref-type="bibr">97</xref>]. These findings highlight the importance of appropriately characterizing the extent of AD-related pathology in the comparison of clinical groups. </p><p>Furthermore, peripheral macrophages are considerable innate immune cells that have the potential of infiltrating the CNS in neuroinflammation [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>]. Nonetheless, the extent of the roles that macrophages play in infiltration in relation with AD has not been fully elucidated. There are studies that have proposed that peripheral myeloid cells could infiltrate brain tissue, thereby mitigating the deposition of A&#946; and cognitive impairments in murine models of AD [<xref rid="B98-life-12-01440" ref-type="bibr">98</xref>,<xref rid="B99-life-12-01440" ref-type="bibr">99</xref>,<xref rid="B100-life-12-01440" ref-type="bibr">100</xref>]. Nevertheless, the interchange of brain-resident myeloid cells that encompass peripheral monocytes did not alter the load of A&#946; in APP/PS1 and APP23 mice models of &#946;-amyloidosis [<xref rid="B101-life-12-01440" ref-type="bibr">101</xref>,<xref rid="B102-life-12-01440" ref-type="bibr">102</xref>]. Subsequently, natural killer cells also have been shown to infiltrate the brain in APP/PS1 mice pathological models [<xref rid="B103-life-12-01440" ref-type="bibr">103</xref>]. In general, the mechanisms utilized by peripheral innate immune cells could be directly related to the AD-related BBB dysfunction, since these BBB alterations could potentially stimulate the infiltration via the deterioration of the cellular and molecular constituents of the pericyte, endothelial, and capillary walls [<xref rid="B104-life-12-01440" ref-type="bibr">104</xref>]. In spite of this, a critical impediment in the success of passive immunotherapy has been the inadequate entry of antibodies into the CNS. In fact, it has been estimated that approximately 0.1% of peripherally administered antibodies can access the brain due to the BBB, thereby hindering the drug availability inside of the brain [<xref rid="B105-life-12-01440" ref-type="bibr">105</xref>,<xref rid="B106-life-12-01440" ref-type="bibr">106</xref>].</p><p>Furthermore, the crosstalk between the peripheral immune system and central immune system is limited due to the scarcity of clinical studies that directly investigate their interchanges, but the current extent of evidence for correlations between acute systemic health scenarios, peripheral inflammation, and CNS-related reactions heavily advocates for the occurrence of communication between both systems [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>]. However, the timing and directionality of the implicated pathways remains to be elucidated to be effectively used in therapeutic modification. Nonetheless, concurrent measurements and comparisons between peripheral inflammation and CNS pathology propose that the levels of the majority of analytes are modestly associated between the compartments [<xref rid="B107-life-12-01440" ref-type="bibr">107</xref>]. AD pathology biomarkers have also been correlated with unique inflammatory signages in CSF and blood, allowing for enhanced accuracy in the classification of AD pathology [<xref rid="B108-life-12-01440" ref-type="bibr">108</xref>,<xref rid="B109-life-12-01440" ref-type="bibr">109</xref>]. The differing inflammatory signatures and profiles advocate for independent and/or joint input of the central and peripheral immune systems in relation to AD, illustrating that the peripheral inflammatory microenvironment is improbable to merely be a downstream secondary effect of CNS dysfunction [<xref rid="B92-life-12-01440" ref-type="bibr">92</xref>].</p></sec></sec><sec sec-type="subjects" id="sec4-life-12-01440"><title>4. Risk Profile of AD Patients</title><p>Universal therapeutics that focus on AD as a homogeneous disease tend to not properly assess the risk profile of the patients receiving the therapeutics [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>]. Geriatric individuals with higher education levels seem to have a decreased prevalence of dementia in comparison to geriatric individuals with no formal education [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>]. In this case, cognitive activity was proposed to reduce the risk of cognitive deterioration via the elevation of the cognitive reserve [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>]. Consequently, individuals with genetic variants&#8212;such as TREM2 R47H or APOE &#949;4 allele&#8212;have also been proposed to be at elevated risk relative to an individual that lacks these variants, even though they may not fall victim to AD until decades later, or even at all [<xref rid="B111-life-12-01440" ref-type="bibr">111</xref>,<xref rid="B112-life-12-01440" ref-type="bibr">112</xref>]. Therefore, there are certain well-documented risks for AD&#8212;including low education, cerebrovascular risk factors, dyslipidemia, APOE &#949;4 allele, and head trauma, to name a few&#8212;that should be taken into account when assessing the risk profile of AD patients [<xref rid="B113-life-12-01440" ref-type="bibr">113</xref>].</p><p>Consequently, vaccines produced should also take into account the risk profile of the patients. To illustrate, preventative vaccines, which target younger members of the population, have a higher and longer antibody response with adjuvant included since they would have enhanced tolerance to the vaccine induced T-cell responses [<xref rid="B114-life-12-01440" ref-type="bibr">114</xref>,<xref rid="B115-life-12-01440" ref-type="bibr">115</xref>]. On the other hand, therapeutic vaccines which target AD patients should induce a rapid antibody response while still maintaining low and durable antibody titers, with the aim of limiting inflammatory responses. In this case, adjuvant should not be included if possible [<xref rid="B116-life-12-01440" ref-type="bibr">116</xref>]. This would allow for less adverse effects in patients with less tolerance [<xref rid="B117-life-12-01440" ref-type="bibr">117</xref>]. Even more, in terms of AD, vaccination against pathogens differs from vaccination against self-peptides such as A&#946;. In this case, the immune tolerance, which is defined by failing to react to self-antigens, is an imperative characteristic of the immune system [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. Several mechanisms are employed in the avoidance of autoimmunity&#8212;such as regulatory T-cell suppression, clonal deletion of elevated affinity autoreactive lymphocytes, and induced insensitivity in matured lymphocytes, among others [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. In &#946;-amyloid vaccines, there could be two opposite risks, with the vaccines not being able to transgress tolerance leading to non-immunogenic effects, with the opposite effect being that the vaccine could result in a severe autoimmune reaction [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>,<xref rid="B119-life-12-01440" ref-type="bibr">119</xref>]. Furthermore, current and future therapeutics should consider that AD patients have been revealed to have blood&#8211;brain barrier (BBB) damage [<xref rid="B120-life-12-01440" ref-type="bibr">120</xref>]. Along with the age-dependent decline in hippocampal BBB, AD therapeutics require the ability to circumvent the BBB, which is relatively difficult, but has been accomplished by various drugs that overcome the BBB and target the CNS [<xref rid="B121-life-12-01440" ref-type="bibr">121</xref>].</p></sec><sec id="sec5-life-12-01440"><title>5. Immunotherapy</title><p>Immunotherapy refers to the field of immunology that localizes treatments via the induction, suppression, or enhancement of an immune response [<xref rid="B122-life-12-01440" ref-type="bibr">122</xref>]. These treatments include vaccines, antibodies, cytokines, and cell-based therapies using immune cells [<xref rid="B123-life-12-01440" ref-type="bibr">123</xref>]. Subsequently, there is active immunotherapy, which aims to stimulate or enhance the immune system of the host, and passive immunotherapy, which encompass therapies that directly supply antibodies to the host (<xref rid="life-12-01440-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B124-life-12-01440" ref-type="bibr">124</xref>]. Immunotherapy originated from the field of bacteriology when W. Busch and F. Fehleisen noted tumor regression in cancer patients after accidental infection with erysipelas [<xref rid="B125-life-12-01440" ref-type="bibr">125</xref>]. Busch then became the first physician to inoculate a cancer patient with erysipelas in 1868, noting shrinkage of the malignancy in the patient [<xref rid="B125-life-12-01440" ref-type="bibr">125</xref>]. Nonetheless, despite Busch&#8217;s and Fehleisen&#8217;s earlier contributions to the field, W.B. Coley is commonly referred to as the &#8220;father of immunotherapy&#8221; due to his treatment of soft tissue and bone sarcoma with Coley&#8217;s toxin, which encompasses a mixture of heat-killed <italic toggle="yes">Serratia marcescens</italic> and streptococcal organisms [<xref rid="B125-life-12-01440" ref-type="bibr">125</xref>].</p><p>Numerous mechanisms of action have been hypothesized for anti-A&#946; antibodies. These mechanisms of action encompass microglial plaque phagocytosis, Fc-receptor-mediated phagocytosis, &#946;-amyloid toxicity neutralization, allosteric effects, and the monomeric efflux of A&#946; from the CNS to circulation, among others (<xref rid="life-12-01440-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. These varying mechanisms could be expected to become more prominent depending on the isotype, concentration, stage of the amyloid deposition process, and epitope specificity of the anti-A&#946; antibodies. However, certain mechanisms have been refuted, such as the peripheral sink hypothesis. With regard to the peripheral sink hypothesis, Georgievska et al. demonstrated that inhibition of A&#946; formation by BACE1 inhibitors is necessary and that the decline of A&#946; in the periphery is not adequate to reduce A&#946; levels in the brain [<xref rid="B126-life-12-01440" ref-type="bibr">126</xref>].</p><p>Other than active and passive immunotherapies, some other therapeutics have been made to harness the immune system in AD. The targeting of immune molecules was consistent with earlier epidemiological research studies that proposed that long-term usage of anti-inflammatory medications were associated with a minimized risk of developing AD [<xref rid="B127-life-12-01440" ref-type="bibr">127</xref>,<xref rid="B128-life-12-01440" ref-type="bibr">128</xref>]. In turn, numerous clinical trials were designed with the intent of suppressing general inflammation. These trials included low dosages of prednisone, non-steroidal anti-inflammatory drugs, NF-&#954;B blockers, statins, and more [<xref rid="B129-life-12-01440" ref-type="bibr">129</xref>,<xref rid="B130-life-12-01440" ref-type="bibr">130</xref>]. Nonetheless, no clear clinical benefits have been elucidated in AD patients. Furthermore, intravenous immunoglobulins have also been utilized clinically for the treatment of numerous infectious and autoimmune diseases and has demonstrated protective effects in animal models of AD [<xref rid="B131-life-12-01440" ref-type="bibr">131</xref>,<xref rid="B132-life-12-01440" ref-type="bibr">132</xref>]. However, intravenous immunoglobulin clinical trials have not yet demonstrated a positive effect [<xref rid="B133-life-12-01440" ref-type="bibr">133</xref>,<xref rid="B134-life-12-01440" ref-type="bibr">134</xref>,<xref rid="B135-life-12-01440" ref-type="bibr">135</xref>]. Consequently, TNF-&#945; is a pro-inflammatory cytokine that is deeply involved in AD and numerous peripheral inflammatory diseases. Peripheral neutralization of TNF-&#945; was shown to be effective at reducing plaques of A&#946; and neuronal dysfunction in 5xFAD mice [<xref rid="B136-life-12-01440" ref-type="bibr">136</xref>]. Furthermore, a 41-subject, double-blind, placebo-controlled phase 2 trial administered Etanercept, which is a TNF-&#945; decoy receptor with a well-tolerated response in the subjects [<xref rid="B137-life-12-01440" ref-type="bibr">137</xref>]. Nonetheless, clinical trials with larger patient cohorts are necessary to further analyze the efficacy of this treatment strategy.</p><p>There have also been anti-aging strategies proposed to halt the aging-related clock of systemic decline. In terms of anti-aging strategies, most studies utilized rodents, but the reporting of molecules with rejuvenating capacity seem to be promising [<xref rid="B46-life-12-01440" ref-type="bibr">46</xref>]. From 2014&#8211;2017, the phase I Plasma for Alzheimer&#8217;s Symptom Amelioration (PLASMA) examined the tolerability, feasibility, and safety of the infusion of blood plasma from younger donors to AD patients with mild-to-moderate cases [<xref rid="B138-life-12-01440" ref-type="bibr">138</xref>]. The trial reported no serious adverse events and concluded that the treatment was well-tolerated, feasible, and safe [<xref rid="B138-life-12-01440" ref-type="bibr">138</xref>]. However, the trial was limited due to the short duration and small sample size of the study. Consequently, in animal models, senolytics have recently appeared as novel anti-aging agents via the targeted destruction of senescent cells [<xref rid="B139-life-12-01440" ref-type="bibr">139</xref>]. Thus, as these anti-aging strategies continue to be developed and employed in larger clinical trials, there could be some promising novel therapeutics for AD.</p><sec id="sec5dot1-life-12-01440"><title>5.1. Active Immunotherapies</title><p>Active immunotherapies involve the administration of an adjuvant which induces an immune response for the production of antibodies [<xref rid="B140-life-12-01440" ref-type="bibr">140</xref>]. The first study of active A&#946; immunotherapy was conducted in 1999 utilizing the PDAPP mouse model where full-length human A&#946; peptide and adjuvant were injected into young PDAPP mice and older PDAPP mice [<xref rid="B75-life-12-01440" ref-type="bibr">75</xref>]. In the young PDAPP mice, the immunization generated A&#946; antibodies which prevented plaque formation and neuritic dystrophy completely and in the older PDAPP mice, the extent of the amyloid deposits decreased significantly [<xref rid="B75-life-12-01440" ref-type="bibr">75</xref>]. Following the model presented in the PDAPP mice, AN-1792 was the first human A&#946; active immunotherapy and was formulated with synthetic full length human A&#946;42 and an adjuvant [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. The QS21 adjuvant was utilized as it favored the T<sub>H</sub>1 polarization of the T-cell response and enhanced antibody responses [<xref rid="B141-life-12-01440" ref-type="bibr">141</xref>]. This study consisted of 372 patients who experienced mild-to-moderate AD; during phase I, patients were injected at an interval of day 0, and then again at weeks 4, 12, and 24 [<xref rid="B142-life-12-01440" ref-type="bibr">142</xref>]. The conclusion of phase 1 trials demonstrated that the vaccine elicited an antibody response to A&#946;42 and cleared plaque in the brain from post-mortem examinations. In phase II trials, AN1792 was injected at 1, 3, 6, 9, and 12 months; however, clinical trials were halted due to patients developing meningoencephalitis which were attributed to the T-cell response to A&#946; [<xref rid="B76-life-12-01440" ref-type="bibr">76</xref>]. Despite AN-1792 clinical trials having adverse effects, the results from this study encouraged the development of new methods of active anti-A&#946; immunotherapy. Currently, CAD106, ABVac40, ACI-24, and UB-311 are the active anti-A&#946; vaccines in phase II trials. Other active anti-A&#946; immunotherapies include the peptide vaccine V950, Vanutide cridificar (ACC-001), and Lu AF20513 (<xref rid="life-12-01440-t001" ref-type="table">Table 1</xref>) [<xref rid="B140-life-12-01440" ref-type="bibr">140</xref>].</p><p>The CAD106 vaccine is developed by Novartis and works by inducing antibody production to reduce beta-amyloid plaques [<xref rid="B143-life-12-01440" ref-type="bibr">143</xref>]. The vaccine is composed of shortened beta-amyloid fragments (A&#946;1-6) to avoid A&#946; T-cell activation [<xref rid="B143-life-12-01440" ref-type="bibr">143</xref>,<xref rid="B144-life-12-01440" ref-type="bibr">144</xref>]. Moreover, there were no signs of meningoencephalitis during the 52 weeks of phase I trial and the vaccine is undergoing safety trials while measuring the antibody response of the vaccine against beta-amyloid plaques during phase II trials [<xref rid="B140-life-12-01440" ref-type="bibr">140</xref>].</p><p>The ABvac40 vaccine is developed by Araclon Biotech and is structured to target the C terminus of A&#946;40 [<xref rid="B145-life-12-01440" ref-type="bibr">145</xref>]. The vaccine is composed of short C-terminal fragments of A&#946;40 and an aluminum hydroxide adjuvant. In order to generate an immune response against A&#946;, the short repeats of the A&#946;40 fragments are conjugated to a keyhole limpet cyanine (KHL) protein [<xref rid="B146-life-12-01440" ref-type="bibr">146</xref>]. During phase I trials, patients with mild-to-moderate AD were enrolled, measuring the safety, immunogenicity, and tolerability of the vaccine [<xref rid="B146-life-12-01440" ref-type="bibr">146</xref>]. As of now, ABvac40 has entered phase II trials where the safety and immune responses are being measured and this study is expected to conclude in December 2022 [<xref rid="B146-life-12-01440" ref-type="bibr">146</xref>].</p><p>The ACI-24 vaccine is developed by AC Immune and contains the A&#946;1-15 epitopes, excluding T-cell epitopes to avoid T-cell responses such as the ones from AN1792 [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>,<xref rid="B147-life-12-01440" ref-type="bibr">147</xref>]. The vaccine is liposome-based and induces &#946;-sheet conformation-specific antibodies through the conformational epitopes of the liposomes [<xref rid="B147-life-12-01440" ref-type="bibr">147</xref>]. During the preclinical trials with transgenic mice, there was success in the improvement in cognition and reduction in A&#946; [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. Currently, ACI-24 is in phase II trials to test the safety, immunogenicity, and tolerability of injections in patients with mild AD [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>].</p><p>The UB-311 vaccine is developed by United Biomedical and contains A&#946;1-14 and linked to a helper T-cell peptide epitope [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. The mixture of peptides would induce B-cell responses while avoiding inflammatory responses from T-cells [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>,<xref rid="B149-life-12-01440" ref-type="bibr">149</xref>]. During phase I trials, A&#946; antibody responses were generated in mild-to-moderate AD patients while the vaccine was safe and tolerable [<xref rid="B149-life-12-01440" ref-type="bibr">149</xref>]. During the phase II trials, the primary goals were to collect further data on safety and immunogenicity [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>].</p><p>Potential active A&#946;-immunotherapies that were being studied but were terminated include peptide vaccine V950, ACC-001, and LU AF20513 [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. The peptide vaccine V950 is composed of A&#946;1-14 conjugated to ISCOMATRIX [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>,<xref rid="B150-life-12-01440" ref-type="bibr">150</xref>]. However, during trials, the study was terminated and there has not been any clinical data presented [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. The vaccine ACC-001 is composed of A&#946;1-7 and is conjugated with a non-toxic form of diphtheria toxin utilizing the QS-21 adjuvant [<xref rid="B151-life-12-01440" ref-type="bibr">151</xref>]. During the phase II trials, it was found that the vaccine was safe and well-tolerated by patients. However, there were no improvements seen within patients resulting in the termination of the study [<xref rid="B151-life-12-01440" ref-type="bibr">151</xref>]. The LU AF20513 vaccine is composed of repeats of A&#946;1-12 while utilizing tetanus toxin [<xref rid="B152-life-12-01440" ref-type="bibr">152</xref>]. The goal of this mixture was to avoid T-cell autoimmune response while activating B cell polyclonal antibodies [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>,<xref rid="B152-life-12-01440" ref-type="bibr">152</xref>]. During the phase I trial, the antibody titers, safety, and tolerability of the vaccine was measured. However, the study was terminated due to data on the efficacy of the vaccine [<xref rid="B152-life-12-01440" ref-type="bibr">152</xref>]. </p><table-wrap position="anchor" id="life-12-01440-t001" orientation="portrait"><object-id pub-id-type="pii">life-12-01440-t001_Table 1</object-id><label>Table 1</label><caption><p>Overview of active A&#946; immunotherapy vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Epitope</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Effects</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AN1792 [<xref rid="B76-life-12-01440" ref-type="bibr">76</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reducing the formation of A&#946; plaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Full length human A&#946;42 and QS21 adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unsafe immune T-cell response resulting in meningoencephalitis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAD106 [<xref rid="B144-life-12-01440" ref-type="bibr">144</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits A&#946; aggregation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shortened beta-amyloid fragments</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe, immunogenic but no reported clinical efficacy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABVac40 [<xref rid="B145-life-12-01440" ref-type="bibr">145</xref>,<xref rid="B153-life-12-01440" ref-type="bibr">153</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;33-40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target the C-terminus of A&#946;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;33-40, KHL, and alum hydroxide adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe, immunogenic, clinical results study to conclude in February 2022</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACI24 [<xref rid="B147-life-12-01440" ref-type="bibr">147</xref>,<xref rid="B154-life-12-01440" ref-type="bibr">154</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit the formation of A&#946; plaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome based</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial to measure safety, immunogenicity and tolerability</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UB-311 [<xref rid="B155-life-12-01440" ref-type="bibr">155</xref>,<xref rid="B156-life-12-01440" ref-type="bibr">156</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induce A&#946; antibody response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-14 and linked to a helper T-cell peptide epitope</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe, immunogenic, and tolerable; but efficacy data are not published</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide vaccine V950 [<xref rid="B150-life-12-01440" ref-type="bibr">150</xref>,<xref rid="B157-life-12-01440" ref-type="bibr">157</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Produce A&#946; antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-14 conjugated to ISCOMATRIX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated study with no clinical data</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACC-001 [<xref rid="B158-life-12-01440" ref-type="bibr">158</xref>,<xref rid="B159-life-12-01440" ref-type="bibr">159</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reducing the formation of A&#946; plaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-7, non-toxic form of diphtheria toxin, QS-21 adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trial terminated due to no improvement in cognition</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LU AF20513 [<xref rid="B152-life-12-01440" ref-type="bibr">152</xref>,<xref rid="B160-life-12-01440" ref-type="bibr">160</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activate B cell polyclonal antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;1-12 and tetanus toxin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated due to efficacy of vaccine</td></tr></tbody></table></table-wrap></sec><sec><title>5.2. Passive Immunotherapies</title><p>Due to the amyloid hypothesis stating that plaque formation via amyloid aggregation is an instigative factor, various research studies have been conducted to determine which definitive isoform of A&#946; engages in the amyloid cascade [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. In passive immunotherapy, antibodies are generated ex vivo and directly injected into the patient [<xref rid="B161-life-12-01440" ref-type="bibr">161</xref>]. This method is beneficial as specific epitopes can be targeted and, with repeated dosing, it results in the formation of anti-antibodies with potential neutralizing effects [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>]. Passive immunotherapy against AD was first demonstrated in PDAPP mice models that received weekly intraperitoneal injections of an N-terminal-specific monoclonal antibody (mAb) against A&#946; and 3D6 mAb [<xref rid="B124-life-12-01440" ref-type="bibr">124</xref>]. Over the course of 6 months, it was found that the mice had reduced A&#946; levels with an increase in Fc-receptor-mediated phagocytosis of A&#946; [<xref rid="B162-life-12-01440" ref-type="bibr">162</xref>]. This led to the creation of several anti-A&#946; antibodies including bapineuzumab, gantenerumab, crenezumab, solanezumab, aducanumab, and BAN 20401 (<xref rid="life-12-01440-t002" ref-type="table">Table 2</xref>).</p><p>Bapineuzumab was the first humanized form of the N-terminal-specific mAb to target A&#946; plaques and induce Fc-receptor-mediated phagocytosis [<xref rid="B163-life-12-01440" ref-type="bibr">163</xref>]. During phase I and II trials, the results indicated that there were cognitive benefits to patients who did not carry the APOE &#949;4 gene, and the overall safety and tolerance were established [<xref rid="B164-life-12-01440" ref-type="bibr">164</xref>]. This prompted bapineuzumab to move into the phase III trial. However, there were no significant treatment effects for cognition and signs of amyloid-related imaging abnormalities (ARIA) were observed resulting in the termination of the study [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>,<xref rid="B164-life-12-01440" ref-type="bibr">164</xref>].</p><p>Gantenerumab is human immunoglobin antibody, binding with subnanomolar affinity to A&#946; conformations in the N-terminal [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. This antibody has been shown to reduce A&#946; levels through the mechanism of inducing phagocytosis after binding to plaques [<xref rid="B165-life-12-01440" ref-type="bibr">165</xref>]. During phase 1 trials, the antibody was safe and tolerable though there were some incidences of ARIA [<xref rid="B166-life-12-01440" ref-type="bibr">166</xref>]. Further studies into phase II and phase III were conducted, but there were no significant differences in efficacy between the primary and secondary measures deeming no clinical benefit overall [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>,<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>].</p><p>Crenezumab is a humanized anti-A&#946; IgG monoclonal antibody that inhibits aggregation of A&#946; in the monomer, oligomer, and fibrillar forms while also assisting in the process of disaggregation [<xref rid="B167-life-12-01440" ref-type="bibr">167</xref>]. During phase 1 trials, the antibody presented adequate safety with no adverse effects, such as vasogenic edema or cerebral microhemorrhage [<xref rid="B168-life-12-01440" ref-type="bibr">168</xref>,<xref rid="B169-life-12-01440" ref-type="bibr">169</xref>]. Based on this conclusion, phase II clinical trials proceeded utilizing a higher concentration of the antibody that was injected intravenously every 4 weeks for a total of 73 weeks [<xref rid="B170-life-12-01440" ref-type="bibr">170</xref>]. An increase in cerebrospinal fluid &#946;-amyloid<sub>1-42</sub> was observed suggesting the targeted engagement in the brain as achieved. However, there was no change in cognition [<xref rid="B170-life-12-01440" ref-type="bibr">170</xref>]. An ultra-sensitive immunoassay conducted on the cerebrospinal fluid (CSF) samples from patients for oligomeric A&#946; found that over 85% of the patients had reduced levels of oligomeric A&#946; in CSF [<xref rid="B170-life-12-01440" ref-type="bibr">170</xref>]. This suggests that the treatment reached the intended target in the brain [<xref rid="B171-life-12-01440" ref-type="bibr">171</xref>].</p><p>Solanezumab is another humanized monoclonal IgG1 antibody that targets the mid-domain of soluble A&#946; [<xref rid="B172-life-12-01440" ref-type="bibr">172</xref>]. During early clinical trials, there were no improvements on patient&#8217;s cognition in moderate AD. However, in patients with mild AD, there was a reduction in the rate of decline [<xref rid="B173-life-12-01440" ref-type="bibr">173</xref>]. In 2020, the trial for phase III which started in 2013 had failed to provide any statistically significant results during the therapy [<xref rid="B174-life-12-01440" ref-type="bibr">174</xref>].</p><p>Aducanumab is a human IgG1 monoclonal antibody that binds to aggregated A&#946; [<xref rid="B175-life-12-01440" ref-type="bibr">175</xref>]. During phase I, a single intravenous infusion was given to patients with mild-to-moderate AD to determine the safety. During the next phase, 1, 3, 6, and 10 mg/kg doses were given to determine the effects on mild AD [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>,<xref rid="B176-life-12-01440" ref-type="bibr">176</xref>]. This phase revealed that there was a statistically significant slowing of clinical decline in all doses. The phase III study of aducanumab was halted in March 2019 due to the lack of meeting primary goals [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. However, in October 2019, the FDA approval process for aducanumab began again [<xref rid="B177-life-12-01440" ref-type="bibr">177</xref>,<xref rid="B178-life-12-01440" ref-type="bibr">178</xref>]. In June 2021, aducanumab was approved for medical use by the FDA but there was controversy surrounding this decision as conflicting results were evaluated over the effectiveness of the treatment [<xref rid="B148-life-12-01440" ref-type="bibr">148</xref>]. The normal route of standard approval was not granted, but the FDA opted for accelerated approval [<xref rid="B179-life-12-01440" ref-type="bibr">179</xref>]. The criticism drawn from this decision related to whether or not there were any cognitive benefits derived from aducanumab or if it will only bring false hope and harm the patient, as it will not actually halt the progression of the disease. Currently, they are waiting for the post marketing trial ending in 2030 to prove that the drug has cognitive benefits [<xref rid="B179-life-12-01440" ref-type="bibr">179</xref>]</p><p>BAN2401 is the humanized version of the mouse mAb158 and targets large, soluble A&#946; protofibrils [<xref rid="B180-life-12-01440" ref-type="bibr">180</xref>]. During the phase 1 trial, the safety and tolerability was tested and there were no reported ARIA in patients with mild-to-moderate AD [<xref rid="B180-life-12-01440" ref-type="bibr">180</xref>]. The dosing regimen was 10 mg/kg every two weeks for four months and the results indicated that the antibody entered the CSF but the efficacy was unknown [<xref rid="B180-life-12-01440" ref-type="bibr">180</xref>]. Phase II trials began to test different intravenous doses to determine the 12-month baseline of cognitive tests and safety [<xref rid="B118-life-12-01440" ref-type="bibr">118</xref>,<xref rid="B180-life-12-01440" ref-type="bibr">180</xref>]. It was announced in 2017 that there were no cognitive benefits during the 12-month time period. However, the protocol for the trial was changed in February 2018 which offered up to 5 years of treatment [<xref rid="B181-life-12-01440" ref-type="bibr">181</xref>]. Currently, a large 4 year BAN2401 study is being conducted to determine the changes in beta-amyloid and cognitive functions and this trial will run until October 2027 [<xref rid="B182-life-12-01440" ref-type="bibr">182</xref>]. </p><table-wrap position="anchor" id="life-12-01440-t002" orientation="portrait"><object-id pub-id-type="pii">life-12-01440-t002_Table 2</object-id><label>Table 2</label><caption><p>Overview of passive A&#946; immunotherapies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Effects</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bapineuzumab [<xref rid="B183-life-12-01440" ref-type="bibr">183</xref>,<xref rid="B184-life-12-01440" ref-type="bibr">184</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target A&#946; plaques and induce Fc-receptor-mediated phagocytosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No clinical benefit and ARIA was observed resulting in termination</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gantenerumab [<xref rid="B165-life-12-01440" ref-type="bibr">165</xref>,<xref rid="B185-life-12-01440" ref-type="bibr">185</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits formation of A&#946; plaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No clinical benefit</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crenezumab [<xref rid="B168-life-12-01440" ref-type="bibr">168</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits A&#946; aggregation and assists with disaggregation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial determining efficacy of treatment</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solanezumab [<xref rid="B186-life-12-01440" ref-type="bibr">186</xref>,<xref rid="B187-life-12-01440" ref-type="bibr">187</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets the mid-domain of soluble A&#946;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No clinical efficacy reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aducanumab [<xref rid="B178-life-12-01440" ref-type="bibr">178</xref>,<xref rid="B188-life-12-01440" ref-type="bibr">188</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduce A&#946; oligomers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III trials terminated due to futility analysis (no cognitive benefits), received approval for medical use by FDA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAN2401 [<xref rid="B182-life-12-01440" ref-type="bibr">182</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduces large, soluble A&#946; protofibrils</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe, tolerable, and unknown efficacy trial will run until October 2027</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec6-life-12-01440"><title>6. Future Direction of AD Immunotherapy</title><p>Immunotherapy should ideally be viewed as a type of precision and personalized medicine. In terms of personalized medicine, the general population has an adopted immunity derived from the parents, meaning that the degree of gene inheritance from parents is varied, and the immune response elicited by the treatment could potentially vary person-to-person [<xref rid="B189-life-12-01440" ref-type="bibr">189</xref>]. Thus, prescribing identical treatments to different hosts could potentially elicit aberrant responses in distinct subjects. Due to this, prescribing individuals different dosages of treatments could be crucial to ideally eliciting similar responses [<xref rid="B190-life-12-01440" ref-type="bibr">190</xref>]. Furthermore, this can also lead to grouping subjects in similar groups based on their dosage and immune profile, with the expectation that the groups will elicit a more homogeneous response, which is precision medicine [<xref rid="B191-life-12-01440" ref-type="bibr">191</xref>].</p><p>In order to ensure more progressive advances in AD immunotherapy, it is crucial to consider that AD substantiates as a heterogeneous multifactorial disorder with a plethora of pathobiological and clinical subtypes [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>,<xref rid="B5-life-12-01440" ref-type="bibr">5</xref>,<xref rid="B7-life-12-01440" ref-type="bibr">7</xref>]. Although there are major subtypes categorized on brain atrophy and tau pathology dissemination&#8212;such as minimal atrophy, typical, limbic predominant, and hippocampal sparing&#8212;there are also a plethora of differing variants, such as mild dementia, cortical atrophy, corticobasal syndromal, primary progressive aphasia, amyloid positive, and immunosenescent variants [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>]. Even more, its polygenic and multifactorial nature lead to various defective genes apportioned through the human genome that may be conducive in the pathogenesis, resulting in neurofibrillary tangles and amyloid deposition [<xref rid="B5-life-12-01440" ref-type="bibr">5</xref>]. Furthering the complexities associated with AD, there are also pathological and clinical intertwines with differing pathologies such as cerebrovascular and Lewy Body disease [<xref rid="B4-life-12-01440" ref-type="bibr">4</xref>,<xref rid="B192-life-12-01440" ref-type="bibr">192</xref>]. Due to this, the likelihood of developing a universal therapeutic agent for AD is slim. Instead, AD immunotherapy should consist of prescreening for the explicit therapeutic to reach the treatment threshold [<xref rid="B121-life-12-01440" ref-type="bibr">121</xref>]. As such, AD immunotherapy should be focused on precision and personalized medicine [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>].</p><p>In recent times, there has been momentous progress in the treatment of some monogenetic disorders, such as cystic fibrosis and various cancers, via the utilization of precision medicine [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>]. However, for other diseases such as AD, precision medicine is still in the initial stages. Currently, most therapeutic and preventative measures for AD are largely ineffective, with the presently utilized therapies centralizing on cholinesterase inhibitor activity, encompassing donepezil, rivastigmine, and galantamine, or suppressing ionotropic glutamatergic signals by memantine [<xref rid="B193-life-12-01440" ref-type="bibr">193</xref>,<xref rid="B194-life-12-01440" ref-type="bibr">194</xref>]. However, all of these medications are only administrated consequent to the onset of symptoms, and have sleep disturbance, nausea, and diarrhea as their frequent side effects [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>].</p><p>The fundamental objective of personalized and precision medicine is to allow physicians and researchers to efficiently and precisely determine the most efficacious therapeutic or preventative treatment for a patient based on their risk profile [<xref rid="B195-life-12-01440" ref-type="bibr">195</xref>]. In order to do this, clinicians routinely utilize information-technology and clinical tests that are economically viable [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>]. This would aid in the extrication of the biological intricacy underlying the patient&#8217;s disease. Furthermore, there are a plethora of prerequisites that must be considered in order to develop a safe and efficacious treatment for AD; such as targeting of at least one of the major pathological proteins, Tau or A&#946;. Furthermore, the impaired immune system of geriatric subjects should be considered, and balance should be brought to the acquired and innate immune systems. Consequently, avoidance of repeated treatment if possible&#8212;while causing no harm to the patient&#8212;would be beneficial. This would allow for the modulation of the AD patient&#8217;s immune system to effectively treat AD [<xref rid="B121-life-12-01440" ref-type="bibr">121</xref>].</p><p>There has recently been a significant advancement in imaging and genomic tools and procedures, with notable advances in the identification of underlying genetic risk variants precisely specifying molecular pathways [<xref rid="B110-life-12-01440" ref-type="bibr">110</xref>,<xref rid="B196-life-12-01440" ref-type="bibr">196</xref>]. Even more, there has also been a progression in the detection technology utilized for pathophysiological processes [<xref rid="B197-life-12-01440" ref-type="bibr">197</xref>]. This has led to the incorporation of precision and personalized medicine in a variety of clinical trials&#8212;including the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease, the Alzheimer&#8217;s Prevention Initiative, and the Dominantly Inherited Alzheimer Network Trial&#8212;with their focal point being patients with recognized AD risk factors, as well as neuroimaging and biofluid biomarkers to aid in the detection of AD onset [<xref rid="B198-life-12-01440" ref-type="bibr">198</xref>,<xref rid="B199-life-12-01440" ref-type="bibr">199</xref>,<xref rid="B200-life-12-01440" ref-type="bibr">200</xref>]. Even though the prosperous and advantageous application of personalized and precision medicine in AD requires a considerable amount of work to appropriately recognize risk factors, AD subgroups, and pathological processes, it is hoped that this application will aid in the production of novel interventions that will advise clinical practice.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.C. and T.Z.; Investigation, T.Z. and J.K.; Resources, C.C.; Writing&#8212;original draft preparation, T.Z. and J.K.; Writing&#8212;review and editing, T.Z., J.K., C.C. and D.S.; Visualization, C.C.; Supervision, C.C.; Project administration, C.C.; Funding acquisition, C.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable. </p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-life-12-01440"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schachter</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>K.L.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Dialogues Clin. Neurosci.</source><year>2000</year><volume>2</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2000.2.2/asschachter</pub-id><pub-id pub-id-type="pmid">22034442</pub-id><pub-id pub-id-type="pmcid">PMC3181599</pub-id></element-citation></ref><ref id="B2-life-12-01440"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>A.A.</given-names></name></person-group><article-title>Therapeutics of Alzheimer&#8217;s disease: Past, present and future</article-title><source>Neuropharmacology</source><year>2014</year><volume>76</volume><issue-part>Pt A</issue-part><fpage>27</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.07.004</pub-id><pub-id pub-id-type="pmid">23891641</pub-id></element-citation></ref><ref id="B3-life-12-01440"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>S.R.</given-names></name></person-group><article-title>Physiological roles of amyloid-beta and implications for its removal in Alzheimer&#8217;s disease</article-title><source>Drugs Aging</source><year>2004</year><volume>21</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.2165/00002512-200421100-00001</pub-id><pub-id pub-id-type="pmid">15287821</pub-id></element-citation></ref><ref id="B4-life-12-01440"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>K.A.</given-names></name></person-group><article-title>Pathobiological Subtypes of Alzheimer Disease</article-title><source>Dement Geriatr. Cogn. Disord.</source><year>2020</year><volume>49</volume><fpage>321</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1159/000508625</pub-id><pub-id pub-id-type="pmid">33429401</pub-id></element-citation></ref><ref id="B5-life-12-01440"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Verhagen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Cabrera</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cavallin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ekman</surname><given-names>U.</given-names></name><name name-style="western"><surname>Muehlboeck</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barroso</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wahlund</surname><given-names>L.O.</given-names></name><etal/></person-group><article-title>Distinct subtypes of Alzheimer&#8217;s disease based on patterns of brain atrophy: Longitudinal trajectories and clinical applications</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>46263</fpage><pub-id pub-id-type="doi">10.1038/srep46263</pub-id><pub-id pub-id-type="pmid">28417965</pub-id><pub-id pub-id-type="pmcid">PMC5394684</pub-id></element-citation></ref><ref id="B6-life-12-01440"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.J.</given-names></name></person-group><article-title>Aging and Alzheimer&#8217;s disease: Comparison and associations from molecular to system level</article-title><source>Aging Cell</source><year>2018</year><volume>17</volume><fpage>e12802</fpage><pub-id pub-id-type="doi">10.1111/acel.12802</pub-id><pub-id pub-id-type="pmid">29963744</pub-id><pub-id pub-id-type="pmcid">PMC6156542</pub-id></element-citation></ref><ref id="B7-life-12-01440"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wahlund</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E.</given-names></name></person-group><article-title>The heterogeneity within Alzheimer&#8217;s disease</article-title><source>Aging</source><year>2018</year><volume>10</volume><fpage>3058</fpage><lpage>3060</lpage><pub-id pub-id-type="doi">10.18632/aging.101638</pub-id><pub-id pub-id-type="pmid">30428453</pub-id><pub-id pub-id-type="pmcid">PMC6286835</pub-id></element-citation></ref><ref id="B8-life-12-01440"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkenbihl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fr&#246;hlich</surname><given-names>H.</given-names></name><collab>Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></person-group><article-title>Unraveling the heterogeneity in Alzheimer&#8217;s disease progression across multiple cohorts and the implications for data-driven disease modeling</article-title><source>Alzheimer&#8217;s Dement</source><year>2021</year><volume>18</volume><fpage>251</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1002/alz.12387</pub-id><pub-id pub-id-type="pmid">34109729</pub-id></element-citation></ref><ref id="B9-life-12-01440"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breijyeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R.</given-names></name></person-group><article-title>Comprehensive Review on Alzheimer&#8217;s Disease: Causes and Treatment</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>5789</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id><pub-id pub-id-type="pmid">33302541</pub-id></element-citation></ref><ref id="B10-life-12-01440"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Karlawish</surname><given-names>J.</given-names></name><etal/></person-group><article-title>NIA-AA Research Framework: Toward a biological definition of Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><year>2018</year><volume>14</volume><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation></ref><ref id="B11-life-12-01440"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.C.</given-names></name></person-group><article-title>Amyloid precursor protein processing and Alzheimer&#8217;s disease</article-title><source>Annu. Rev. Neurosci.</source><year>2011</year><volume>34</volume><fpage>185</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113613</pub-id><pub-id pub-id-type="pmid">21456963</pub-id><pub-id pub-id-type="pmcid">PMC3174086</pub-id></element-citation></ref><ref id="B12-life-12-01440"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoyagi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Condello</surname><given-names>C.</given-names></name><name name-style="western"><surname>St&#246;hr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Woerman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Duinen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ingelsson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A&#946; and tau prion-like activities decline with longevity in the Alzheimer&#8217;s disease human brain</article-title><source>Sci. Transl. Med.</source><year>2019</year><volume>11</volume><fpage>eaat8462</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aat8462</pub-id><pub-id pub-id-type="pmid">31043574</pub-id><pub-id pub-id-type="pmcid">PMC6640844</pub-id></element-citation></ref><ref id="B13-life-12-01440"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cline</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Bicca</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Viola</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>W.L.</given-names></name></person-group><article-title>The Amyloid-&#946; Oligomer Hypothesis: Beginning of the Third Decade</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2018</year><volume>64</volume><fpage>S567</fpage><lpage>S610</lpage><pub-id pub-id-type="doi">10.3233/JAD-179941</pub-id><pub-id pub-id-type="pmid">29843241</pub-id><pub-id pub-id-type="pmcid">PMC6004937</pub-id></element-citation></ref><ref id="B14-life-12-01440"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bartolini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Davani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andrisano</surname><given-names>V.</given-names></name></person-group><article-title>Advanced analytical methodologies in Alzheimer&#8217;s disease drug discovery</article-title><source>J. Pharm. Biomed. Anal.</source><year>2020</year><volume>178</volume><fpage>112899</fpage><pub-id pub-id-type="doi">10.1016/j.jpba.2019.112899</pub-id><pub-id pub-id-type="pmid">31606562</pub-id></element-citation></ref><ref id="B15-life-12-01440"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name></person-group><source>Alzheimer&#8217;s Disease: Drug Discovery</source><publisher-name>Exon Publications</publisher-name><publisher-loc>Brisbane, Australia</publisher-loc><year>2020</year><pub-id pub-id-type="pmid">33400453</pub-id></element-citation></ref><ref id="B16-life-12-01440"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hanger</surname><given-names>D.P.</given-names></name></person-group><article-title>Roles of tau protein in health and disease</article-title><source>Acta Neuropathol.</source><year>2017</year><volume>133</volume><fpage>665</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1707-9</pub-id><pub-id pub-id-type="pmid">28386764</pub-id><pub-id pub-id-type="pmcid">PMC5390006</pub-id></element-citation></ref><ref id="B17-life-12-01440"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Grundke-Iqbal</surname><given-names>I.</given-names></name></person-group><article-title>Tau in Alzheimer disease and related tauopathies</article-title><source>Curr. Alzheimer Res.</source><year>2010</year><volume>7</volume><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.2174/156720510793611592</pub-id><pub-id pub-id-type="pmid">20678074</pub-id><pub-id pub-id-type="pmcid">PMC3090074</pub-id></element-citation></ref><ref id="B18-life-12-01440"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name></person-group><article-title>Invited Review&#8212;Understanding cause and effect in Alzheimer&#8217;s pathophysiology: Implications for clinical trials</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>2020</year><volume>46</volume><fpage>623</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1111/nan.12642</pub-id><pub-id pub-id-type="pmid">32643143</pub-id></element-citation></ref><ref id="B19-life-12-01440"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</article-title><source>Cell</source><year>2019</year><volume>179</volume><fpage>312</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></element-citation></ref><ref id="B20-life-12-01440"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gendreau</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>G.F.</given-names></name></person-group><article-title>Tangles, Toxicity, and Tau Secretion in AD&#8212;New Approaches to a Vexing Problem</article-title><source>Front. Neurol.</source><year>2013</year><volume>4</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.3389/fneur.2013.00160</pub-id><pub-id pub-id-type="pmid">24151487</pub-id><pub-id pub-id-type="pmcid">PMC3801151</pub-id></element-citation></ref><ref id="B21-life-12-01440"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.S.</given-names></name></person-group><article-title>History and progress of hypotheses and clinical trials for Alzheimer&#8217;s disease</article-title><source>Signal Transduct. Target Ther.</source><year>2019</year><volume>4</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1038/s41392-019-0063-8</pub-id><pub-id pub-id-type="pmid">31637009</pub-id><pub-id pub-id-type="pmcid">PMC6799833</pub-id></element-citation></ref><ref id="B22-life-12-01440"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group><article-title>Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy</article-title><source>Nat. Rev. Neurol.</source><year>2013</year><volume>9</volume><fpage>106</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2012.263</pub-id><pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></element-citation></ref><ref id="B23-life-12-01440"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paudel</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Papageorgiou</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Piperi</surname><given-names>C.</given-names></name></person-group><article-title>APOE Genotype and Alzheimer&#8217;s Disease: The Influence of Lifestyle and Environmental Factors</article-title><source>ACS Chem. Neurosci.</source><year>2021</year><volume>12</volume><fpage>2749</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.1c00295</pub-id><pub-id pub-id-type="pmid">34275270</pub-id></element-citation></ref><ref id="B24-life-12-01440"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.</given-names></name><name name-style="western"><surname>George-Hyslop</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Pericak-Vance</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Rosi</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Gusella</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Crapper-MacLachlan</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>M.J.</given-names></name></person-group><article-title>Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#8217;s disease</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>1467</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1212/WNL.43.8.1467</pub-id><pub-id pub-id-type="pmid">8350998</pub-id></element-citation></ref><ref id="B25-life-12-01440"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Roses</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pericak-Vance</surname><given-names>M.A.</given-names></name></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#8217;s disease in late onset families</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1126/science.8346443</pub-id><pub-id pub-id-type="pmid">8346443</pub-id></element-citation></ref><ref id="B26-life-12-01440"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caulfield</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group><article-title>Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies</article-title><source>Nat. Rev. Neurol.</source><year>2019</year><volume>15</volume><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0228-7</pub-id><pub-id pub-id-type="pmid">31367008</pub-id><pub-id pub-id-type="pmcid">PMC7055192</pub-id></element-citation></ref><ref id="B27-life-12-01440"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerreiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bras</surname><given-names>J.</given-names></name></person-group><article-title>The age factor in Alzheimer&#8217;s disease</article-title><source>Genome Med.</source><year>2015</year><volume>7</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s13073-015-0232-5</pub-id><pub-id pub-id-type="pmid">26482651</pub-id><pub-id pub-id-type="pmcid">PMC4617238</pub-id></element-citation></ref><ref id="B28-life-12-01440"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Appay</surname><given-names>V.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frasca</surname><given-names>D.</given-names></name><name name-style="western"><surname>F&#252;l&#246;p</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sauce</surname><given-names>D.</given-names></name><name name-style="western"><surname>Larbi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cossarizza</surname><given-names>A.</given-names></name></person-group><article-title>Aging of the immune system: Focus on inflammation and vaccination</article-title><source>Eur. J. Immunol.</source><year>2016</year><volume>46</volume><fpage>2286</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1002/eji.201546178</pub-id><pub-id pub-id-type="pmid">27595500</pub-id><pub-id pub-id-type="pmcid">PMC5156481</pub-id></element-citation></ref><ref id="B29-life-12-01440"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name></person-group><article-title>Peripheral immune system in aging and Alzheimer&#8217;s disease</article-title><source>Mol. Neurodegener.</source><year>2018</year><volume>13</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s13024-018-0284-2</pub-id><pub-id pub-id-type="pmid">30285785</pub-id><pub-id pub-id-type="pmcid">PMC6169078</pub-id></element-citation></ref><ref id="B30-life-12-01440"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V.D.</given-names></name></person-group><article-title>Drivers of age-related inflammation and strategies for healthspan extension</article-title><source>Immunol. Rev.</source><year>2015</year><volume>265</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/imr.12295</pub-id><pub-id pub-id-type="pmid">25879284</pub-id><pub-id pub-id-type="pmcid">PMC4400872</pub-id></element-citation></ref><ref id="B31-life-12-01440"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>van de Veerdonk</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name></person-group><article-title>Inflammasome-independent regulation of IL-1-family cytokines</article-title><source>Annu. Rev. Immunol.</source><year>2015</year><volume>33</volume><fpage>49</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112306</pub-id><pub-id pub-id-type="pmid">25493334</pub-id></element-citation></ref><ref id="B32-life-12-01440"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>A.</given-names></name></person-group><article-title>Activation and regulation of the inflammasomes</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>397</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/nri3452</pub-id><pub-id pub-id-type="pmid">23702978</pub-id><pub-id pub-id-type="pmcid">PMC3807999</pub-id></element-citation></ref><ref id="B33-life-12-01440"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lartigue</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bolen</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gaudilliere</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ganio</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fragiadakis</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Douchet</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/nm.4267</pub-id><pub-id pub-id-type="pmid">28092664</pub-id><pub-id pub-id-type="pmcid">PMC5320935</pub-id></element-citation></ref><ref id="B34-life-12-01440"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youm</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Albarado</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Ravussin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pistell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laque</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging</article-title><source>Cell Metab.</source><year>2013</year><volume>18</volume><fpage>519</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.09.010</pub-id><pub-id pub-id-type="pmid">24093676</pub-id><pub-id pub-id-type="pmcid">PMC4017327</pub-id></element-citation></ref><ref id="B35-life-12-01440"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kizer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Odden</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Zeki Al Hazzouri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>A.M.</given-names></name></person-group><article-title>Trajectories of function and biomarkers with age: The CHS All Stars Study</article-title><source>Int. J. Epidemiol.</source><year>2016</year><volume>45</volume><fpage>1135</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw092</pub-id><pub-id pub-id-type="pmid">27272182</pub-id><pub-id pub-id-type="pmcid">PMC5841627</pub-id></element-citation></ref><ref id="B36-life-12-01440"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Jimenez</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Eling</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Vallejos</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Kolodziejczyk</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stojic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Stubbington</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Teichmann</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Aging increases cell-to-cell transcriptional variability upon immune stimulation</article-title><source>Science</source><year>2017</year><volume>355</volume><fpage>1433</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1126/science.aah4115</pub-id><pub-id pub-id-type="pmid">28360329</pub-id><pub-id pub-id-type="pmcid">PMC5405862</pub-id></element-citation></ref><ref id="B37-life-12-01440"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arda</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Mignardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beausang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bottino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Quake</surname><given-names>S.R.</given-names></name></person-group><article-title>Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>321</fpage><lpage>330.e14</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.004</pub-id><pub-id pub-id-type="pmid">28965763</pub-id><pub-id pub-id-type="pmcid">PMC6047899</pub-id></element-citation></ref><ref id="B38-life-12-01440"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vallania</surname><given-names>F.</given-names></name><name name-style="western"><surname>Warsinske</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Donato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schaffert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Dvorak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Utz</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Single-Cell Chromatin Modification Profiling Reveals Increased Epigenetic Variations with Aging</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>1385</fpage><lpage>1397.e14</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.079</pub-id><pub-id pub-id-type="pmid">29706550</pub-id><pub-id pub-id-type="pmcid">PMC5984186</pub-id></element-citation></ref><ref id="B39-life-12-01440"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolich-&#381;ugich</surname><given-names>J.</given-names></name></person-group><article-title>The twilight of immunity: Emerging concepts in aging of the immune system</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0006-x</pub-id><pub-id pub-id-type="pmid">29242543</pub-id></element-citation></ref><ref id="B40-life-12-01440"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ucar</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#225;rquez</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Marches</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Uyar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stitzel</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Palucka</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>The chromatin accessibility signature of human immune aging stems from CD8</article-title><source>J. Exp. Med.</source><year>2017</year><volume>214</volume><fpage>3123</fpage><lpage>3144</lpage><pub-id pub-id-type="doi">10.1084/jem.20170416</pub-id><pub-id pub-id-type="pmid">28904110</pub-id><pub-id pub-id-type="pmcid">PMC5626401</pub-id></element-citation></ref><ref id="B41-life-12-01440"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Stolberg</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Chensue</surname><given-names>S.W.</given-names></name></person-group><article-title>Cutting edge: Central memory CD8 T cells in aged mice are virtual memory cells</article-title><source>J. Immunol.</source><year>2013</year><volume>191</volume><fpage>5793</fpage><lpage>5796</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302509</pub-id><pub-id pub-id-type="pmid">24227783</pub-id><pub-id pub-id-type="pmcid">PMC3858473</pub-id></element-citation></ref><ref id="B42-life-12-01440"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharpless</surname><given-names>N.E.</given-names></name></person-group><article-title>Senescence in Health and Disease</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>1000</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.015</pub-id><pub-id pub-id-type="pmid">28575665</pub-id><pub-id pub-id-type="pmcid">PMC5643029</pub-id></element-citation></ref><ref id="B43-life-12-01440"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-Esp&#237;n</surname><given-names>D.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M.</given-names></name></person-group><article-title>Cellular senescence: From physiology to pathology</article-title><source>Nat. Rev. Mol. Cell Biol</source><year>2014</year><volume>15</volume><fpage>482</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/nrm3823</pub-id><pub-id pub-id-type="pmid">24954210</pub-id></element-citation></ref><ref id="B44-life-12-01440"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franceschi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J.</given-names></name></person-group><article-title>Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases</article-title><source>J. Gerontol. A Biol Sci. Med. Sci.</source><year>2014</year><volume>69</volume><issue>(Suppl. 1)</issue><fpage>S4</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1093/gerona/glu057</pub-id><pub-id pub-id-type="pmid">24833586</pub-id></element-citation></ref><ref id="B45-life-12-01440"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copp&#233;</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Rodier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Desprez</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J.</given-names></name></person-group><article-title>Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor</article-title><source>PLoS Biol.</source><year>2008</year><volume>6</volume><fpage>2853</fpage><lpage>2868</lpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0060301</pub-id><pub-id pub-id-type="pmid">19053174</pub-id><pub-id pub-id-type="pmcid">PMC2592359</pub-id></element-citation></ref><ref id="B46-life-12-01440"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>Ageing, neurodegeneration and brain rejuvenation</article-title><source>Nature</source><year>2016</year><volume>539</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature20411</pub-id><pub-id pub-id-type="pmid">27830812</pub-id><pub-id pub-id-type="pmcid">PMC5172605</pub-id></element-citation></ref><ref id="B47-life-12-01440"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villeda</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mosher</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Britschgi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stan</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Fainberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Eggel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The ageing systemic milieu negatively regulates neurogenesis and cognitive function</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nature10357</pub-id><pub-id pub-id-type="pmid">21886162</pub-id><pub-id pub-id-type="pmcid">PMC3170097</pub-id></element-citation></ref><ref id="B48-life-12-01440"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Manohar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Regalado</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Pancoast</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle</article-title><source>Science</source><year>2014</year><volume>344</volume><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1126/science.1251152</pub-id><pub-id pub-id-type="pmid">24797481</pub-id><pub-id pub-id-type="pmcid">PMC4104429</pub-id></element-citation></ref><ref id="B49-life-12-01440"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middeldorp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lehallier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villeda</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Miedema</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Czirr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mosher</surname><given-names>K.I.</given-names></name><etal/></person-group><article-title>Preclinical Assessment of Young Blood Plasma for Alzheimer Disease</article-title><source>JAMA Neurol.</source><year>2016</year><volume>73</volume><fpage>1325</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.3185</pub-id><pub-id pub-id-type="pmid">27598869</pub-id><pub-id pub-id-type="pmcid">PMC5172595</pub-id></element-citation></ref><ref id="B50-life-12-01440"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mosher</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Abbey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>James</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Berdnik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Tingle</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Human umbilical cord plasma proteins revitalize hippocampal function in aged mice</article-title><source>Nature</source><year>2017</year><volume>544</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nature22067</pub-id><pub-id pub-id-type="pmid">28424512</pub-id><pub-id pub-id-type="pmcid">PMC5586222</pub-id></element-citation></ref><ref id="B51-life-12-01440"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groh</surname><given-names>N.</given-names></name><name name-style="western"><surname>B&#252;hler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>van Nierop</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>F&#228;ndrich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>F.</given-names></name><name name-style="western"><surname>David</surname><given-names>D.C.</given-names></name></person-group><article-title>Age-Dependent Protein Aggregation Initiates Amyloid-&#946; Aggregation</article-title><source>Front. Aging Neurosci.</source><year>2017</year><volume>9</volume><fpage>138</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2017.00138</pub-id><pub-id pub-id-type="pmid">28567012</pub-id><pub-id pub-id-type="pmcid">PMC5434662</pub-id></element-citation></ref><ref id="B52-life-12-01440"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomiyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iso</surname><given-names>H.</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takuma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohnishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Teraoka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sakama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>4845</fpage><lpage>4856</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5825-09.2010</pub-id><pub-id pub-id-type="pmid">20371804</pub-id><pub-id pub-id-type="pmcid">PMC6632783</pub-id></element-citation></ref><ref id="B53-life-12-01440"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kametani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>M.</given-names></name></person-group><article-title>Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer&#8217;s Disease</article-title><source>Front. Neurosci.</source><year>2018</year><volume>12</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00025</pub-id><pub-id pub-id-type="pmid">29440986</pub-id><pub-id pub-id-type="pmcid">PMC5797629</pub-id></element-citation></ref><ref id="B54-life-12-01440"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ben-Shaanan</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dubovik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Azulay-Debby</surname><given-names>H.</given-names></name><name name-style="western"><surname>Boshnak</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Koren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rolls</surname><given-names>A.</given-names></name></person-group><article-title>High-dimensional, single-cell characterization of the brain&#8217;s immune compartment</article-title><source>Nat. Neurosci.</source><year>2017</year><volume>20</volume><fpage>1300</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/nn.4610</pub-id><pub-id pub-id-type="pmid">28758994</pub-id></element-citation></ref><ref id="B55-life-12-01440"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cardon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ziv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>8180</fpage><lpage>8185</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402268101</pub-id><pub-id pub-id-type="pmid">15141078</pub-id><pub-id pub-id-type="pmcid">PMC419577</pub-id></element-citation></ref><ref id="B56-life-12-01440"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ron</surname><given-names>N.</given-names></name><name name-style="western"><surname>Butovsky</surname><given-names>O.</given-names></name><name name-style="western"><surname>Landa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sudai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood</article-title><source>Nat. Neurosci.</source><year>2006</year><volume>9</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/nn1629</pub-id><pub-id pub-id-type="pmid">16415867</pub-id></element-citation></ref><ref id="B57-life-12-01440"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filiano</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tustison</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>W.</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Overall</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Gadani</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Unexpected role of interferon-&#947; in regulating neuronal connectivity and social behaviour</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>425</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/nature18626</pub-id><pub-id pub-id-type="pmid">27409813</pub-id><pub-id pub-id-type="pmcid">PMC4961620</pub-id></element-citation></ref><ref id="B58-life-12-01440"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derecki</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Cardani</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Quinnies</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Crihfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name></person-group><article-title>Regulation of learning and memory by meningeal immunity: A key role for IL-4</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>1067</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1084/jem.20091419</pub-id><pub-id pub-id-type="pmid">20439540</pub-id><pub-id pub-id-type="pmcid">PMC2867291</pub-id></element-citation></ref><ref id="B59-life-12-01440"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deczkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>David</surname><given-names>E.</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kertser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berkutzki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barnett-Itzhaki</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bezalel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1126/science.1252945</pub-id><pub-id pub-id-type="pmid">25147279</pub-id><pub-id pub-id-type="pmcid">PMC4869326</pub-id></element-citation></ref><ref id="B60-life-12-01440"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balusu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brkic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Libert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>R.E.</given-names></name></person-group><article-title>The choroid plexus-cerebrospinal fluid interface in Alzheimer&#8217;s disease: More than just a barrier</article-title><source>Neural Regen. Res.</source><year>2016</year><volume>11</volume><fpage>534</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.180372</pub-id><pub-id pub-id-type="pmid">27212900</pub-id><pub-id pub-id-type="pmcid">PMC4870896</pub-id></element-citation></ref><ref id="B61-life-12-01440"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ron-Harel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deczkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shifrut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ndifon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mirlas-Neisberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cardon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaknin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cahalon</surname><given-names>L.</given-names></name><etal/></person-group><article-title>CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>2264</fpage><lpage>2269</lpage><pub-id pub-id-type="doi">10.1073/pnas.1211270110</pub-id><pub-id pub-id-type="pmid">23335631</pub-id><pub-id pub-id-type="pmcid">PMC3568380</pub-id></element-citation></ref><ref id="B62-life-12-01440"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deczkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baruch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology</article-title><source>Trends Immunol.</source><year>2016</year><volume>37</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.it.2016.01.006</pub-id><pub-id pub-id-type="pmid">26877243</pub-id></element-citation></ref><ref id="B63-life-12-01440"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montecino-Rodriguez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berent-Maoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dorshkind</surname><given-names>K.</given-names></name></person-group><article-title>Causes, consequences, and reversal of immune system aging</article-title><source>J. Clin. Investig.</source><year>2013</year><volume>123</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1172/JCI64096</pub-id><pub-id pub-id-type="pmid">23454758</pub-id><pub-id pub-id-type="pmcid">PMC3582124</pub-id></element-citation></ref><ref id="B64-life-12-01440"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarasoff-Conway</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Carare</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Glodzik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fieremans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Axel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rusinek</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>B.V.</given-names></name><etal/></person-group><article-title>Clearance systems in the brain-implications for Alzheimer disease</article-title><source>Nat. Rev. Neurol.</source><year>2015</year><volume>11</volume><fpage>457</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.119</pub-id><pub-id pub-id-type="pmid">26195256</pub-id><pub-id pub-id-type="pmcid">PMC4694579</pub-id></element-citation></ref><ref id="B65-life-12-01440"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cronk</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Filiano</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Louveau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Geraci</surname><given-names>N.</given-names></name><name name-style="western"><surname>Acton</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia</article-title><source>J. Exp. Med.</source><year>2018</year><volume>215</volume><fpage>1627</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1084/jem.20180247</pub-id><pub-id pub-id-type="pmid">29643186</pub-id><pub-id pub-id-type="pmcid">PMC5987928</pub-id></element-citation></ref><ref id="B66-life-12-01440"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butovsky</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kunis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koronyo-Hamaoui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer&#8217;s disease model</article-title><source>Eur. J. Neurosci.</source><year>2007</year><volume>26</volume><fpage>413</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05652.x</pub-id><pub-id pub-id-type="pmid">17623022</pub-id></element-citation></ref><ref id="B67-life-12-01440"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulrich</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ulland</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Elucidating the Role of TREM2 in Alzheimer&#8217;s Disease</article-title><source>Neuron</source><year>2017</year><volume>94</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.042</pub-id><pub-id pub-id-type="pmid">28426958</pub-id></element-citation></ref><ref id="B68-life-12-01440"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ochi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ozaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Numata</surname><given-names>S.</given-names></name><etal/></person-group><article-title>TREM2 mRNA Expression in Leukocytes Is Increased in Alzheimer&#8217;s Disease and Schizophrenia</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0136835</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0136835</pub-id><pub-id pub-id-type="pmid">26332043</pub-id><pub-id pub-id-type="pmcid">PMC4557831</pub-id></element-citation></ref><ref id="B69-life-12-01440"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>A.S.L.</given-names></name><name name-style="western"><surname>Vipin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.K.W.</given-names></name><name name-style="western"><surname>Chander</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>S.K.S.</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer&#8217;s Disease and Amnestic Mild Cognitive Impairment</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2017</year><volume>58</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.3233/JAD-161277</pub-id><pub-id pub-id-type="pmid">28453482</pub-id></element-citation></ref><ref id="B70-life-12-01440"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zenaro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pietronigro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Della Bianca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Piacentino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marongiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Budui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Angiari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dusi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neutrophils promote Alzheimer&#8217;s disease-like pathology and cognitive decline via LFA-1 integrin</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nm.3913</pub-id><pub-id pub-id-type="pmid">26214837</pub-id></element-citation></ref><ref id="B71-life-12-01440"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabbita</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kobritz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poteshkina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Varadarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zemlan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Harris-White</surname><given-names>M.E.</given-names></name></person-group><article-title>Oral TNF&#945; Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0137305</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0137305</pub-id><pub-id pub-id-type="pmid">26436670</pub-id><pub-id pub-id-type="pmcid">PMC4593589</pub-id></element-citation></ref><ref id="B72-life-12-01440"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaskin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Finley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.M.</given-names></name></person-group><article-title>Human antibodies reactive with beta-amyloid protein in Alzheimer&#8217;s disease</article-title><source>J. Exp. Med.</source><year>1993</year><volume>177</volume><fpage>1181</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1084/jem.177.4.1181</pub-id><pub-id pub-id-type="pmid">8459212</pub-id><pub-id pub-id-type="pmcid">PMC2190957</pub-id></element-citation></ref><ref id="B73-life-12-01440"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dodel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Buerger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bales</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Reduced levels of amyloid beta-peptide antibody in Alzheimer disease</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>801</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1212/WNL.57.5.801</pub-id><pub-id pub-id-type="pmid">11552007</pub-id></element-citation></ref><ref id="B74-life-12-01440"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tuzova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dobbs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kryscio</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer&#8217;s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: Implications for disease pathogenesis and vaccine development</article-title><source>Neuromol. Med.</source><year>2003</year><volume>3</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1385/NMM:3:1:29</pub-id><pub-id pub-id-type="pmid">12665674</pub-id></element-citation></ref><ref id="B75-life-12-01440"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grajeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guido</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson-Wood</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/22124</pub-id><pub-id pub-id-type="pmid">10408445</pub-id></element-citation></ref><ref id="B76-life-12-01440"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Eisner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rovira</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Forette</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159740.16984.3C</pub-id><pub-id pub-id-type="pmid">15883316</pub-id></element-citation></ref><ref id="B77-life-12-01440"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foroutan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Tarride</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Florez</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.</given-names></name></person-group><article-title>Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer&#8217;s disease: A systematic review and network meta-analysis</article-title><source>Clin. Investig. Med.</source><year>2019</year><volume>42</volume><fpage>E53</fpage><lpage>E65</lpage><pub-id pub-id-type="doi">10.25011/cim.v42i1.32393</pub-id><pub-id pub-id-type="pmid">30904037</pub-id></element-citation></ref><ref id="B78-life-12-01440"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Bonito-Oliva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakmar</surname><given-names>T.P.</given-names></name></person-group><article-title>Update on Alzheimer&#8217;s Disease Therapy and Prevention Strategies</article-title><source>Annu. Rev. Med.</source><year>2017</year><volume>68</volume><fpage>413</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-042915-103753</pub-id><pub-id pub-id-type="pmid">28099083</pub-id></element-citation></ref><ref id="B79-life-12-01440"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Can Alzheimer disease be prevented by amyloid-beta immunotherapy?</article-title><source>Nat. Rev. Neurol.</source><year>2010</year><volume>6</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.219</pub-id><pub-id pub-id-type="pmid">20140000</pub-id><pub-id pub-id-type="pmcid">PMC2864089</pub-id></element-citation></ref><ref id="B80-life-12-01440"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Nagele</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagele</surname><given-names>R.G.</given-names></name></person-group><article-title>Autoantibodies: Double agents in human disease</article-title><source>Sci. Transl. Med.</source><year>2013</year><volume>5</volume><fpage>186fs119</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3006288</pub-id><pub-id pub-id-type="pmid">23698377</pub-id></element-citation></ref><ref id="B81-life-12-01440"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagele</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>DeMarshall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kosciuk</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Nagele</surname><given-names>R.G.</given-names></name></person-group><article-title>Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e60726</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060726</pub-id><pub-id pub-id-type="pmid">23589757</pub-id><pub-id pub-id-type="pmcid">PMC3617628</pub-id></element-citation></ref><ref id="B82-life-12-01440"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMarshall</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Nagele</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Godsey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goldwaser</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kosciuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thayasivam</surname><given-names>U.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name><name name-style="western"><surname>Belinka</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Detection of Alzheimer&#8217;s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers</article-title><source>Alzheimer&#8217;s Dement</source><year>2016</year><volume>3</volume><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2016.03.002</pub-id><pub-id pub-id-type="pmid">27239548</pub-id><pub-id pub-id-type="pmcid">PMC4879649</pub-id></element-citation></ref><ref id="B83-life-12-01440"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsh</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Abud</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lakatos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karimzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Davtyan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fote</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weinger</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>T.E.</given-names></name><etal/></person-group><article-title>The adaptive immune system restrains Alzheimer&#8217;s disease pathogenesis by modulating microglial function</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E1316</fpage><lpage>E1325</lpage><pub-id pub-id-type="doi">10.1073/pnas.1525466113</pub-id><pub-id pub-id-type="pmid">26884167</pub-id><pub-id pub-id-type="pmcid">PMC4780638</pub-id></element-citation></ref><ref id="B84-life-12-01440"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relkin</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Rissman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Rafii</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A phase 3 trial of IV immunoglobulin for Alzheimer disease</article-title><source>Neurology</source><year>2017</year><volume>88</volume><fpage>1768</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000003904</pub-id><pub-id pub-id-type="pmid">28381506</pub-id><pub-id pub-id-type="pmcid">PMC5409846</pub-id></element-citation></ref><ref id="B85-life-12-01440"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Togo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iseki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>K.</given-names></name></person-group><article-title>Occurrence of T cells in the brain of Alzheimer&#8217;s disease and other neurological diseases</article-title><source>J. Neuroimmunol.</source><year>2002</year><volume>124</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(01)00496-9</pub-id><pub-id pub-id-type="pmid">11958825</pub-id></element-citation></ref><ref id="B86-life-12-01440"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itagaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>H.</given-names></name></person-group><article-title>Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer&#8217;s disease brain tissue</article-title><source>Neurosci. Lett.</source><year>1988</year><volume>91</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(88)90690-8</pub-id><pub-id pub-id-type="pmid">2972943</pub-id></element-citation></ref><ref id="B87-life-12-01440"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>McQuillan</surname><given-names>K.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name></person-group><article-title>IFN-&#947; Production by amyloid &#946;-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer&#8217;s disease</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>2241</fpage><lpage>2251</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200947</pub-id><pub-id pub-id-type="pmid">23365075</pub-id></element-citation></ref><ref id="B88-life-12-01440"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Merlini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sp&#228;ni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gericke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schweizer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Enzmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kulic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Suter</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nitsch</surname><given-names>R.M.</given-names></name></person-group><article-title>T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer&#8217;s disease-like cerebral amyloidosis</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>54</volume><fpage>211</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.02.009</pub-id><pub-id pub-id-type="pmid">26872418</pub-id></element-citation></ref><ref id="B89-life-12-01440"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monsonego</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imitola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Petrovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zota</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nemirovsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>H.L.</given-names></name></person-group><article-title>Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer&#8217;s disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>5048</fpage><lpage>5053</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506209103</pub-id><pub-id pub-id-type="pmid">16549802</pub-id><pub-id pub-id-type="pmcid">PMC1458792</pub-id></element-citation></ref><ref id="B90-life-12-01440"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Strominger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Biton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemirovsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Monsonego</surname><given-names>A.</given-names></name></person-group><article-title>Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301707</pub-id><pub-id pub-id-type="pmid">24307730</pub-id></element-citation></ref><ref id="B91-life-12-01440"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arendash</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mamcarz</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ethell</surname><given-names>D.W.</given-names></name></person-group><article-title>Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer&#8217;s mice without infiltrating the CNS</article-title><source>Neurobiol. Dis.</source><year>2009</year><volume>34</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2008.12.015</pub-id><pub-id pub-id-type="pmid">19167499</pub-id><pub-id pub-id-type="pmcid">PMC5546306</pub-id></element-citation></ref><ref id="B92-life-12-01440"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettcher</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Tansey</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Doroth&#233;e</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name></person-group><article-title>Peripheral and central immune system crosstalk in Alzheimer disease&#8212;A research prospectus</article-title><source>Nat. Rev. Neurol.</source><year>2021</year><volume>17</volume><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/s41582-021-00549-x</pub-id><pub-id pub-id-type="pmid">34522039</pub-id><pub-id pub-id-type="pmcid">PMC8439173</pub-id></element-citation></ref><ref id="B93-life-12-01440"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Franzmeier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Su&#225;rez-Calvet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morenas-Rodriguez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.A.A.</given-names></name><name name-style="western"><surname>Kleinberger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Piccio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cruchaga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dichgans</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer&#8217;s disease</article-title><source>Sci. Transl. Med.</source><year>2019</year><volume>11</volume><fpage>eaav6221</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aav6221</pub-id><pub-id pub-id-type="pmid">31462511</pub-id><pub-id pub-id-type="pmcid">PMC7050285</pub-id></element-citation></ref><ref id="B94-life-12-01440"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillai</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bena</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bebek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bonner-Jackson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neilsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer&#8217;s disease</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2020</year><volume>7</volume><fpage>1225</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1002/acn3.51109</pub-id><pub-id pub-id-type="pmid">32634865</pub-id><pub-id pub-id-type="pmcid">PMC7359114</pub-id></element-citation></ref><ref id="B95-life-12-01440"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Buchhave</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Minthon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janciauskiene</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name></person-group><article-title>CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer&#8217;s disease</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e30525</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0030525</pub-id><pub-id pub-id-type="pmid">22303443</pub-id><pub-id pub-id-type="pmcid">PMC3268759</pub-id></element-citation></ref><ref id="B96-life-12-01440"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipa</surname><given-names>R.</given-names></name><name name-style="western"><surname>das Neves</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer&#8217;s disease and their correlation with cognitive decline</article-title><source>Neurobiol. Aging</source><year>2019</year><volume>76</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.12.019</pub-id><pub-id pub-id-type="pmid">30711675</pub-id></element-citation></ref><ref id="B97-life-12-01440"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Savard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Labont&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosa-Neto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weitz</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Town</surname><given-names>T.</given-names></name><name name-style="western"><surname>Breitner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>A.S.D.N.</given-names></name><name name-style="western"><surname>Group</surname><given-names>P.-A.R.</given-names></name></person-group><article-title>Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer&#8217;s Disease Pathogenesis</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2018</year><volume>63</volume><fpage>577</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.3233/JAD-170887</pub-id><pub-id pub-id-type="pmid">29660934</pub-id><pub-id pub-id-type="pmcid">PMC5929310</pub-id></element-citation></ref><ref id="B98-life-12-01440"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simard</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Soulet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gowing</surname><given-names>G.</given-names></name><name name-style="western"><surname>Julien</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rivest</surname><given-names>S.</given-names></name></person-group><article-title>Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#8217;s disease</article-title><source>Neuron</source><year>2006</year><volume>49</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.01.022</pub-id><pub-id pub-id-type="pmid">16476660</pub-id></element-citation></ref><ref id="B99-life-12-01440"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Khoury</surname><given-names>J.</given-names></name><name name-style="western"><surname>Toft</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Means</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Geula</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luster</surname><given-names>A.D.</given-names></name></person-group><article-title>Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/nm1555</pub-id><pub-id pub-id-type="pmid">17351623</pub-id></element-citation></ref><ref id="B100-life-12-01440"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rivest</surname><given-names>S.</given-names></name></person-group><article-title>CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>6208</fpage><lpage>6220</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0299-11.2011</pub-id><pub-id pub-id-type="pmid">21508244</pub-id><pub-id pub-id-type="pmcid">PMC6632958</pub-id></element-citation></ref><ref id="B101-life-12-01440"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varvel</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Grathwohl</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Resch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jucker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neher</surname><given-names>J.J.</given-names></name></person-group><article-title>Replacement of brain-resident myeloid cells does not alter cerebral amyloid-&#946; deposition in mouse models of Alzheimer&#8217;s disease</article-title><source>J. Exp. Med.</source><year>2015</year><volume>212</volume><fpage>1803</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1084/jem.20150478</pub-id><pub-id pub-id-type="pmid">26458770</pub-id><pub-id pub-id-type="pmcid">PMC4612086</pub-id></element-citation></ref><ref id="B102-life-12-01440"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prokop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Drost</surname><given-names>N.</given-names></name><name name-style="western"><surname>Handrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wegner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>F.L.</given-names></name></person-group><article-title>Impact of peripheral myeloid cells on amyloid-&#946; pathology in Alzheimer&#8217;s disease-like mice</article-title><source>J. Exp. Med.</source><year>2015</year><volume>212</volume><fpage>1811</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1084/jem.20150479</pub-id><pub-id pub-id-type="pmid">26458768</pub-id><pub-id pub-id-type="pmcid">PMC4612091</pub-id></element-citation></ref><ref id="B103-life-12-01440"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Minogue</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Denieffe</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name></person-group><article-title>Glial Activation in A&#946;PP/PS1 Mice is Associated with Infiltration of IFN&#947;-Producing Cells</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2013</year><volume>37</volume><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3233/JAD-130539</pub-id><pub-id pub-id-type="pmid">23780663</pub-id></element-citation></ref><ref id="B104-life-12-01440"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>B.V.</given-names></name></person-group><article-title>Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders</article-title><source>Nat. Rev. Neurol.</source><year>2018</year><volume>14</volume><fpage>133</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2017.188</pub-id><pub-id pub-id-type="pmid">29377008</pub-id><pub-id pub-id-type="pmcid">PMC5829048</pub-id></element-citation></ref><ref id="B105-life-12-01440"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poduslo</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.T.</given-names></name></person-group><article-title>Macromolecular permeability across the blood-nerve and blood-brain barriers</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>5705</fpage><lpage>5709</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.12.5705</pub-id><pub-id pub-id-type="pmid">8202551</pub-id><pub-id pub-id-type="pmcid">PMC44065</pub-id></element-citation></ref><ref id="B106-life-12-01440"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Depboylu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Noelker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Behr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Behe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dodel</surname><given-names>R.</given-names></name></person-group><article-title>Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>Neurosci. Lett.</source><year>2009</year><volume>449</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2008.08.083</pub-id><pub-id pub-id-type="pmid">18786612</pub-id></element-citation></ref><ref id="B107-life-12-01440"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettcher</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casaletto</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer&#8217;s Disease Pathology and Neuronal Damage</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2018</year><volume>62</volume><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.3233/JAD-170602</pub-id><pub-id pub-id-type="pmid">29439331</pub-id><pub-id pub-id-type="pmcid">PMC6007886</pub-id></element-citation></ref><ref id="B108-life-12-01440"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oikonomidi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tautvydait&#279;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dayon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Migliavacca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kirkland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Severin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wojcik</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Markers of neuroinflammation associated with Alzheimer&#8217;s disease pathology in older adults</article-title><source>Brain Behav. Immun.</source><year>2017</year><volume>62</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.020</pub-id><pub-id pub-id-type="pmid">28161476</pub-id></element-citation></ref><ref id="B109-life-12-01440"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whelan</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagle</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Vijayaraghavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fitz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Samad</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol. Commun.</source><year>2019</year><volume>7</volume><fpage>169</fpage><pub-id pub-id-type="doi">10.1186/s40478-019-0795-2</pub-id><pub-id pub-id-type="pmid">31694701</pub-id><pub-id pub-id-type="pmcid">PMC6836495</pub-id></element-citation></ref><ref id="B110-life-12-01440"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name></person-group><article-title>Toward precision medicine in Alzheimer&#8217;s disease</article-title><source>Ann. Transl. Med.</source><year>2016</year><volume>4</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.21037/atm.2016.03.05</pub-id><pub-id pub-id-type="pmid">27127760</pub-id><pub-id pub-id-type="pmcid">PMC4828743</pub-id></element-citation></ref><ref id="B111-life-12-01440"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leoni</surname><given-names>V.</given-names></name></person-group><article-title>The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer&#8217;s disease</article-title><source>Clin. Chem. Lab. Med.</source><year>2011</year><volume>49</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2011.088</pub-id><pub-id pub-id-type="pmid">21388338</pub-id></element-citation></ref><ref id="B112-life-12-01440"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng-Hathaway</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Reed-Geaghan</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Jay</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Casali</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Bemiller</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Puntambekar</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>von Saucken</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Karlo</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Moutinho</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer&#8217;s disease</article-title><source>Mol. Neurodegener.</source><year>2018</year><volume>13</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13024-018-0262-8</pub-id><pub-id pub-id-type="pmid">29859094</pub-id><pub-id pub-id-type="pmcid">PMC5984804</pub-id></element-citation></ref><ref id="B113-life-12-01440"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.V.F.</given-names></name><name name-style="western"><surname>Loures</surname><given-names>C.M.G.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>L.C.V.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>K.B.G.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>M.D.G.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: Risk factors and potentially protective measures</article-title><source>J. Biomed. Sci.</source><year>2019</year><volume>26</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12929-019-0524-y</pub-id><pub-id pub-id-type="pmid">31072403</pub-id><pub-id pub-id-type="pmcid">PMC6507104</pub-id></element-citation></ref><ref id="B114-life-12-01440"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Boutajangout</surname><given-names>A.</given-names></name></person-group><article-title>Vaccination as a therapeutic approach to Alzheimer&#8217;s disease</article-title><source>Mt. Sinai J. Med.</source><year>2010</year><volume>77</volume><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/msj.20156</pub-id><pub-id pub-id-type="pmid">20101719</pub-id><pub-id pub-id-type="pmcid">PMC3026780</pub-id></element-citation></ref><ref id="B115-life-12-01440"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.J.</given-names></name></person-group><article-title>Prophylactic and therapeutic vaccines against Alzheimer&#8217;s disease</article-title><source>Sheng Wu Gong Cheng Xue Bao</source><year>2003</year><volume>19</volume><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">15971572</pub-id></element-citation></ref><ref id="B116-life-12-01440"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vickers</surname><given-names>J.C.</given-names></name></person-group><article-title>A vaccine against Alzheimer&#8217;s disease: Developments to date</article-title><source>Drugs Aging</source><year>2002</year><volume>19</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.2165/00002512-200219070-00002</pub-id><pub-id pub-id-type="pmid">12182685</pub-id></element-citation></ref><ref id="B117-life-12-01440"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacabelos</surname><given-names>R.</given-names></name></person-group><article-title>How plausible is an Alzheimer&#8217;s disease vaccine?</article-title><source>Expert. Opin. Drug Discov.</source><year>2020</year><volume>15</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/17460441.2019.1667329</pub-id><pub-id pub-id-type="pmid">31526140</pub-id></element-citation></ref><ref id="B118-life-12-01440"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantile</surname><given-names>F.</given-names></name><name name-style="western"><surname>Prisco</surname><given-names>A.</given-names></name></person-group><article-title>Vaccination against &#946;-Amyloid as a Strategy for the Prevention of Alzheimer&#8217;s Disease</article-title><source>Biology</source><year>2020</year><volume>9</volume><elocation-id>425</elocation-id><pub-id pub-id-type="doi">10.3390/biology9120425</pub-id><pub-id pub-id-type="pmcid">PMC7761159</pub-id><pub-id pub-id-type="pmid">33260956</pub-id></element-citation></ref><ref id="B119-life-12-01440"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brambilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sanvito</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roccatagliata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bergami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pluchino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uccelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Martino</surname><given-names>G.</given-names></name></person-group><article-title>Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1093/brain/awg031</pub-id><pub-id pub-id-type="pmid">12538398</pub-id></element-citation></ref><ref id="B120-life-12-01440"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Amezcua</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Blood-brain barrier breakdown in the aging human hippocampus</article-title><source>Neuron</source><year>2015</year><volume>85</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.032</pub-id><pub-id pub-id-type="pmid">25611508</pub-id><pub-id pub-id-type="pmcid">PMC4350773</pub-id></element-citation></ref><ref id="B121-life-12-01440"><label>121.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cacabelos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cacabelos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Torrelas</surname><given-names>C.</given-names></name></person-group><article-title>Personalized Medicine of Alzheimer&#8217;s Disease</article-title><source>Handbook of Pharmacogenomics and Stratified Medicine</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2014</year><volume>Volume 27</volume><fpage>563</fpage><lpage>615</lpage></element-citation></ref><ref id="B122-life-12-01440"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wraith</surname><given-names>D.C.</given-names></name></person-group><article-title>The Future of Immunotherapy: A 20-Year Perspective</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1668</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01668</pub-id><pub-id pub-id-type="pmid">29234325</pub-id><pub-id pub-id-type="pmcid">PMC5712390</pub-id></element-citation></ref><ref id="B123-life-12-01440"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>I.D.</given-names></name></person-group><article-title>An overview of cancer immunotherapy</article-title><source>Immunol. Cell Biol.</source><year>2000</year><volume>78</volume><fpage>179</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1711.2000.00906.x</pub-id><pub-id pub-id-type="pmid">10849106</pub-id></element-citation></ref><ref id="B124-life-12-01440"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brody</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Active and passive immunotherapy for neurodegenerative disorders</article-title><source>Annu. Rev. Neurosci.</source><year>2008</year><volume>31</volume><fpage>175</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.31.060407.125529</pub-id><pub-id pub-id-type="pmid">18352830</pub-id><pub-id pub-id-type="pmcid">PMC2561172</pub-id></element-citation></ref><ref id="B125-life-12-01440"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oelschlaeger</surname><given-names>T.A.</given-names></name></person-group><article-title>Bacteria as tumor therapeutics?</article-title><source>Bioeng. Bugs</source><year>2010</year><volume>1</volume><fpage>146</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.4161/bbug.1.2.11248</pub-id><pub-id pub-id-type="pmid">21326940</pub-id><pub-id pub-id-type="pmcid">PMC3026455</pub-id></element-citation></ref><ref id="B126-life-12-01440"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgievska</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gustavsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lundkvist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neelissen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eketj&#228;ll</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramberg</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bueters</surname><given-names>T.</given-names></name><name name-style="western"><surname>Agerman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jur&#233;us</surname><given-names>A.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Revisiting the peripheral sink hypothesis: Inhibiting BACE1 activity in the periphery does not alter &#946;-amyloid levels in the CNS</article-title><source>J. Neurochem.</source><year>2015</year><volume>132</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1111/jnc.12937</pub-id><pub-id pub-id-type="pmid">25156639</pub-id></element-citation></ref><ref id="B127-life-12-01440"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGeer</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>E.G.</given-names></name></person-group><article-title>Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2006</year><volume>9</volume><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.3233/JAD-2006-9S330</pub-id><pub-id pub-id-type="pmid">16914866</pub-id></element-citation></ref><ref id="B128-life-12-01440"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>in t&#8217; Veld</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ruitenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>van Duijn</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Stijnen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>B.H.</given-names></name></person-group><article-title>Nonsteroidal antiinflammatory drugs and the risk of Alzheimer&#8217;s disease</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>345</volume><fpage>1515</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa010178</pub-id><pub-id pub-id-type="pmid">11794217</pub-id></element-citation></ref><ref id="B129-life-12-01440"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrieu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lovestone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name></person-group><article-title>Prevention of sporadic Alzheimer&#8217;s disease: Lessons learned from clinical trials and future directions</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>926</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00153-2</pub-id><pub-id pub-id-type="pmid">26213339</pub-id></element-citation></ref><ref id="B130-life-12-01440"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Adapt-Fs Research Group</collab></person-group><article-title>Follow-up evaluation of cognitive function in the randomized Alzheimer&#8217;s Disease Anti-inflammatory Prevention Trial and its Follow-up Study</article-title><source>Alzheimer&#8217;s Dement</source><year>2015</year><volume>11</volume><fpage>216</fpage><lpage>225.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.03.009</pub-id><pub-id pub-id-type="pmid">25022541</pub-id><pub-id pub-id-type="pmcid">PMC4287453</pub-id></element-citation></ref><ref id="B131-life-12-01440"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudduth</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Greenstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilcock</surname><given-names>D.M.</given-names></name></person-group><article-title>Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers A&#946; in APP/PS1 mice along a different time course than anti-A&#946; antibodies</article-title><source>J. Neurosci.</source><year>2013</year><volume>33</volume><fpage>9684</fpage><lpage>9692</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1220-13.2013</pub-id><pub-id pub-id-type="pmid">23739965</pub-id><pub-id pub-id-type="pmcid">PMC3839584</pub-id></element-citation></ref><ref id="B132-life-12-01440"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Counts</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mufson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lahiri</surname><given-names>D.K.</given-names></name></person-group><article-title>Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer&#8217;s disease</article-title><source>J. Clin. Immunol.</source><year>2014</year><volume>34</volume><issue>(Suppl. 1)</issue><fpage>S80</fpage><lpage>S85</lpage><pub-id pub-id-type="doi">10.1007/s10875-014-0020-9</pub-id><pub-id pub-id-type="pmid">24760109</pub-id><pub-id pub-id-type="pmcid">PMC4293701</pub-id></element-citation></ref><ref id="B133-life-12-01440"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>D.A.</given-names></name></person-group><article-title>Intravenous immunoglobulin and Alzheimer&#8217;s disease: What now?</article-title><source>J. Neuroinflamm.</source><year>2013</year><volume>10</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-10-70</pub-id><pub-id pub-id-type="pmid">23735288</pub-id><pub-id pub-id-type="pmcid">PMC3720252</pub-id></element-citation></ref><ref id="B134-life-12-01440"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rominger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bartenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>F&#246;rster</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Popp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alferink</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer&#8217;s disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial</article-title><source>Lancet Neurol</source><year>2013</year><volume>12</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70014-0</pub-id><pub-id pub-id-type="pmid">23375965</pub-id><pub-id pub-id-type="pmcid">PMC4986921</pub-id></element-citation></ref><ref id="B135-life-12-01440"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relkin</surname><given-names>N.</given-names></name></person-group><article-title>Clinical trials of intravenous immunoglobulin for Alzheimer&#8217;s disease</article-title><source>J. Clin. Immunol.</source><year>2014</year><volume>34</volume><issue>(Suppl. 1)</issue><fpage>S74</fpage><lpage>S79</lpage><pub-id pub-id-type="doi">10.1007/s10875-014-0041-4</pub-id><pub-id pub-id-type="pmid">24760112</pub-id></element-citation></ref><ref id="B136-life-12-01440"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacPherson</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Sompol</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kannarkat</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sniffen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wildner</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tansey</surname><given-names>M.G.</given-names></name></person-group><article-title>Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice</article-title><source>Neurobiol. Dis.</source><year>2017</year><volume>102</volume><fpage>81</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2017.02.010</pub-id><pub-id pub-id-type="pmid">28237313</pub-id><pub-id pub-id-type="pmcid">PMC5464789</pub-id></element-citation></ref><ref id="B137-life-12-01440"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butchart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brook</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>V.</given-names></name><name name-style="western"><surname>Teeling</surname><given-names>J.</given-names></name><name name-style="western"><surname>P&#252;ntener</surname><given-names>U.</given-names></name><name name-style="western"><surname>Culliford</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharples</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharif</surname><given-names>S.</given-names></name><name name-style="western"><surname>McFarlane</surname><given-names>B.</given-names></name><name name-style="western"><surname>Raybould</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial</article-title><source>Neurology</source><year>2015</year><volume>84</volume><fpage>2161</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001617</pub-id><pub-id pub-id-type="pmid">25934853</pub-id><pub-id pub-id-type="pmcid">PMC4451045</pub-id></element-citation></ref><ref id="B138-life-12-01440"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Deutsch</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Coburn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaudioso</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Marcal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boumis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bet</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial</article-title><source>JAMA Neurol.</source><year>2019</year><volume>76</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.3288</pub-id><pub-id pub-id-type="pmid">30383097</pub-id><pub-id pub-id-type="pmcid">PMC6439869</pub-id></element-citation></ref><ref id="B139-life-12-01440"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Childs</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Gluscevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Laberge</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Marquess</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dananberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Deursen</surname><given-names>J.M.</given-names></name></person-group><article-title>Senescent cells: An emerging target for diseases of ageing</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>718</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.116</pub-id><pub-id pub-id-type="pmid">28729727</pub-id><pub-id pub-id-type="pmcid">PMC5942225</pub-id></element-citation></ref><ref id="B140-life-12-01440"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name></person-group><article-title>Active immunotherapy options for Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2014</year><volume>6</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/alzrt237</pub-id><pub-id pub-id-type="pmid">24476230</pub-id><pub-id pub-id-type="pmcid">PMC3979042</pub-id></element-citation></ref><ref id="B141-life-12-01440"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lennick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marciani</surname><given-names>D.</given-names></name></person-group><article-title>Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex</article-title><source>J. Immunol.</source><year>1991</year><volume>146</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">1987271</pub-id></element-citation></ref><ref id="B142-life-12-01440"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossor</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M.</given-names></name></person-group><article-title>Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1563</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159743.08996.99</pub-id><pub-id pub-id-type="pmid">15883317</pub-id></element-citation></ref><ref id="B143-life-12-01440"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandenberghe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sovago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marotta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sanchez-Valle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Active A&#946; immunotherapy CAD106 in Alzheimer&#8217;s disease: A phase 2b study</article-title><source>Alzheimer&#8217;s Dement</source><year>2017</year><volume>3</volume><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2016.12.003</pub-id><pub-id pub-id-type="pmid">29067316</pub-id><pub-id pub-id-type="pmcid">PMC5651373</pub-id></element-citation></ref><ref id="B144-life-12-01440"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Minthon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Floesser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imbert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dumortier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lundmark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and antibody response of active A&#946; immunotherapy with CAD106 in patients with Alzheimer&#8217;s disease: Randomised, double-blind, placebo-controlled, first-in-human study</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70140-0</pub-id><pub-id pub-id-type="pmid">22677258</pub-id></element-citation></ref><ref id="B145-life-12-01440"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacosta</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pascual-Lucas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pesini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Casabona</surname><given-names>D.</given-names></name><name name-style="western"><surname>P&#233;rez-Grijalba</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marcos-Campos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sarasa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Canudas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Badi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Monle&#243;n</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Safety, tolerability and immunogenicity of an active anti-A&#946;</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2018</year><volume>10</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0340-8</pub-id><pub-id pub-id-type="pmid">29378651</pub-id><pub-id pub-id-type="pmcid">PMC5789644</pub-id></element-citation></ref><ref id="B146-life-12-01440"><label>146.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients with a-MCI or Vm-AD</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT03461276" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/record/NCT03461276</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B147-life-12-01440"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chuard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Giriens</surname><given-names>V.</given-names></name><name name-style="western"><surname>Meerschman</surname><given-names>C.</given-names></name><name name-style="western"><surname>van der Auwera</surname><given-names>I.</given-names></name><name name-style="western"><surname>van Leuven</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weingertner</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>9810</fpage><lpage>9815</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703137104</pub-id><pub-id pub-id-type="pmid">17517595</pub-id><pub-id pub-id-type="pmcid">PMC1887581</pub-id></element-citation></ref><ref id="B148-life-12-01440"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiss</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Montufar</surname><given-names>N.</given-names></name><name name-style="western"><surname>DeLeon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinkhasov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomolin</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Arain</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Stecker</surname><given-names>M.M.</given-names></name></person-group><article-title>Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans</article-title><source>Neurologist</source><year>2021</year><volume>26</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1097/NRL.0000000000000320</pub-id><pub-id pub-id-type="pmid">33646990</pub-id></element-citation></ref><ref id="B149-life-12-01440"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Finstad</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>De Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>UB-311, a novel UBITh</article-title><source>Alzheimer&#8217;s Dement</source><year>2017</year><volume>3</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.03.005</pub-id><pub-id pub-id-type="pmcid">PMC5651432</pub-id><pub-id pub-id-type="pmid">29067332</pub-id></element-citation></ref><ref id="B150-life-12-01440"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigaeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Doorn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hak</surname><given-names>E.</given-names></name></person-group><article-title>Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0154757</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154757</pub-id><pub-id pub-id-type="pmid">27149269</pub-id><pub-id pub-id-type="pmcid">PMC4858302</pub-id></element-citation></ref><ref id="B151-life-12-01440"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Di</surname><given-names>J.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Werth</surname><given-names>J.</given-names></name><name name-style="western"><surname>LePrince Leterme</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shadman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brashear</surname><given-names>H.R.</given-names></name></person-group><article-title>A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer&#8217;s Disease</article-title><source>J. Prev. Alzheimer&#8217;s Dis.</source><year>2016</year><volume>3</volume><fpage>192</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.14283/jpad.2016.118</pub-id><pub-id pub-id-type="pmid">29199321</pub-id></element-citation></ref><ref id="B152-life-12-01440"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davtyan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghochikyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petrushina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hovakimyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davtyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poghosyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marleau</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Movsesyan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kiyatkin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer&#8217;s disease: Prelude to a clinical trial</article-title><source>J. Neurosci.</source><year>2013</year><volume>33</volume><fpage>4923</fpage><lpage>4934</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4672-12.2013</pub-id><pub-id pub-id-type="pmid">23486963</pub-id><pub-id pub-id-type="pmcid">PMC3634356</pub-id></element-citation></ref><ref id="B153-life-12-01440"><label>153.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients with a-MCI or Vm-AD</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03461276" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03461276</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B154-life-12-01440"><label>154.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>A Study of ACI-24 in Adults with Down Syndrome</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04373616" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04373616</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B155-life-12-01440"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease drug development pipeline: 2019</article-title><source>Alzheimer&#8217;s Dement.</source><year>2019</year><volume>5</volume><fpage>272</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2019.05.008</pub-id><pub-id pub-id-type="pmcid">PMC6617248</pub-id><pub-id pub-id-type="pmid">31334330</pub-id></element-citation></ref><ref id="B156-life-12-01440"><label>156.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer&#8217;s Disease (AD) Patients</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02551809" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02551809</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B157-life-12-01440"><label>157.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>A Study of V950 in People with Alzheimer Disease (V950-001 AM7)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00464334" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT00464334</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B158-life-12-01440"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadowsky</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Le Prince Leterme</surname><given-names>G.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshiyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer&#8217;s Disease</article-title><source>Curr. Alzheimer Res.</source><year>2017</year><volume>14</volume><fpage>696</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.2174/1567205014666170117101537</pub-id><pub-id pub-id-type="pmid">28124589</pub-id><pub-id pub-id-type="pmcid">PMC5543567</pub-id></element-citation></ref><ref id="B159-life-12-01440"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sadowsky</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leterme</surname><given-names>G.L.P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer&#8217;s Disease</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2016</year><volume>51</volume><fpage>1131</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.3233/JAD-150376</pub-id><pub-id pub-id-type="pmid">26967206</pub-id></element-citation></ref><ref id="B160-life-12-01440"><label>160.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>Study with Lu AF20513 in Patients with Mild Alzheimer&#8217;s Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03819699" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03819699</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-17">(accessed on 17 September 2021)</date-in-citation></element-citation></ref><ref id="B161-life-12-01440"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease: Past, present and future</article-title><source>Front. Aging Neurosci.</source><year>2014</year><volume>6</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2014.00114</pub-id><pub-id pub-id-type="pmid">24959143</pub-id><pub-id pub-id-type="pmcid">PMC4051211</pub-id></element-citation></ref><ref id="B162-life-12-01440"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N.R.</given-names></name></person-group><article-title>Passive immunotherapies targeting A&#946; and tau in Alzheimer&#8217;s disease</article-title><source>Neurobiol. Dis.</source><year>2020</year><volume>144</volume><fpage>105010</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2020.105010</pub-id><pub-id pub-id-type="pmid">32682954</pub-id><pub-id pub-id-type="pmcid">PMC7365083</pub-id></element-citation></ref><ref id="B163-life-12-01440"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delnomdedieu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Atassi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brashear</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ness</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kupiec</surname><given-names>J.W.</given-names></name></person-group><article-title>First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2016</year><volume>8</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13195-016-0177-y</pub-id><pub-id pub-id-type="pmid">26925577</pub-id><pub-id pub-id-type="pmcid">PMC4772335</pub-id></element-citation></ref><ref id="B164-life-12-01440"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Doody</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>2061</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c67808</pub-id><pub-id pub-id-type="pmid">19923550</pub-id><pub-id pub-id-type="pmcid">PMC2790221</pub-id></element-citation></ref><ref id="B165-life-12-01440"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohrmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Knoflach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oroszlan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rauchenberger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>W.F.</given-names></name><etal/></person-group><article-title>Gantenerumab: A novel human anti-A&#946; antibody demonstrates sustained cerebral amyloid-&#946; binding and elicits cell-mediated removal of human amyloid-&#946;</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2012</year><volume>28</volume><fpage>49</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.3233/JAD-2011-110977</pub-id><pub-id pub-id-type="pmid">21955818</pub-id></element-citation></ref><ref id="B166-life-12-01440"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piazza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name></person-group><article-title>Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer&#8217;s Disease: Need for Prognostic Biomarkers?</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2016</year><volume>52</volume><fpage>417</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.3233/JAD-160122</pub-id><pub-id pub-id-type="pmid">27031492</pub-id></element-citation></ref><ref id="B167-life-12-01440"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ostaszewski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mengel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Target engagement in an alzheimer trial: Crenezumab lowers amyloid &#946; oligomers in cerebrospinal fluid</article-title><source>Ann. Neurol.</source><year>2019</year><volume>86</volume><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1002/ana.25513</pub-id><pub-id pub-id-type="pmid">31168802</pub-id><pub-id pub-id-type="pmcid">PMC6771589</pub-id></element-citation></ref><ref id="B168-life-12-01440"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ostrowitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Honigberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Quartino</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2020</year><volume>12</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-0580-2</pub-id><pub-id pub-id-type="pmid">31969177</pub-id><pub-id pub-id-type="pmcid">PMC6977279</pub-id></element-citation></ref><ref id="B169-life-12-01440"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guthrie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sink</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Blondeau</surname><given-names>K.</given-names></name><name name-style="western"><surname>Quartino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dolton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrasco-Triguero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer&#8217;s Disease Treated with Escalating Doses for up to 133 Weeks</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2020</year><volume>76</volume><fpage>967</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.3233/JAD-200134</pub-id><pub-id pub-id-type="pmid">32568196</pub-id><pub-id pub-id-type="pmcid">PMC7505005</pub-id></element-citation></ref><ref id="B170-life-12-01440"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Brody</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Friesenhahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brunstein</surname><given-names>F.</given-names></name><etal/></person-group><article-title>ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease</article-title><source>Neurology</source><year>2018</year><volume>90</volume><fpage>e1889</fpage><lpage>e1897</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000005550</pub-id><pub-id pub-id-type="pmid">29695589</pub-id><pub-id pub-id-type="pmcid">PMC5962917</pub-id></element-citation></ref><ref id="B171-life-12-01440"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Honigberg</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Friesenhahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brunstein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quartino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer&#8217;s disease (BLAZE)</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2018</year><volume>10</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0424-5</pub-id><pub-id pub-id-type="pmid">30231896</pub-id><pub-id pub-id-type="pmcid">PMC6146627</pub-id></element-citation></ref><ref id="B172-life-12-01440"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumner</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Asuni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Teeling</surname><given-names>J.L.</given-names></name></person-group><article-title>Antibody Engineering for Optimized Immunotherapy in Alzheimer&#8217;s Disease</article-title><source>Front. Neurosci.</source><year>2018</year><volume>12</volume><fpage>254</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00254</pub-id><pub-id pub-id-type="pmid">29740272</pub-id><pub-id pub-id-type="pmcid">PMC5924811</pub-id></element-citation></ref><ref id="B173-life-12-01440"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sethuraman</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety and biomarker effects of solanezumab in patients with Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><year>2012</year><volume>8</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.09.224</pub-id><pub-id pub-id-type="pmid">22672770</pub-id></element-citation></ref><ref id="B174-life-12-01440"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siemers</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Sundell</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Case</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sethuraman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu-Seifert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dowsett</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Pontecorvo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Demattos</surname><given-names>R.</given-names></name></person-group><article-title>Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer&#8217;s disease patients</article-title><source>Alzheimer&#8217;s Dement</source><year>2016</year><volume>12</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.06.1893</pub-id><pub-id pub-id-type="pmid">26238576</pub-id></element-citation></ref><ref id="B175-life-12-01440"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhillon</surname><given-names>S.</given-names></name></person-group><article-title>Aducanumab: First Approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>1437</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01569-z</pub-id><pub-id pub-id-type="pmid">34324167</pub-id></element-citation></ref><ref id="B176-life-12-01440"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevigny</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bussi&#232;re</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weinreb</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>L.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dunstan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The antibody aducanumab reduces A&#946; plaques in Alzheimer&#8217;s disease</article-title><source>Nature</source><year>2016</year><volume>537</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nature19323</pub-id><pub-id pub-id-type="pmid">27582220</pub-id></element-citation></ref><ref id="B177-life-12-01440"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muralidharan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>J.M.</given-names></name></person-group><article-title>Antibodies to watch in 2020</article-title><source>MAbs</source><year>2020</year><volume>12</volume><fpage>1703531</fpage><pub-id pub-id-type="doi">10.1080/19420862.2019.1703531</pub-id><pub-id pub-id-type="pmid">31847708</pub-id><pub-id pub-id-type="pmcid">PMC6973335</pub-id></element-citation></ref><ref id="B178-life-12-01440"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>L.</given-names></name></person-group><article-title>A resurrection of aducanumab for Alzheimer&#8217;s disease</article-title><source>Lancet Neurol.</source><year>2020</year><volume>19</volume><fpage>111</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30480-6</pub-id><pub-id pub-id-type="pmid">31978357</pub-id></element-citation></ref><ref id="B179-life-12-01440"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>Controversial Alzheimer&#8217;s drug approval could affect other diseases</article-title><source>Nature</source><year>2021</year><volume>595</volume><fpage>162</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-01763-9</pub-id><pub-id pub-id-type="pmid">34193994</pub-id></element-citation></ref><ref id="B180-life-12-01440"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logovinsky</surname><given-names>V.</given-names></name><name name-style="western"><surname>Satlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaplow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>G.</given-names></name><name name-style="western"><surname>Basun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lannfelt</surname><given-names>L.</given-names></name></person-group><article-title>Safety and tolerability of BAN2401--a clinical study in Alzheimer&#8217;s disease with a protofibril selective A&#946; antibody</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2016</year><volume>8</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s13195-016-0181-2</pub-id><pub-id pub-id-type="pmid">27048170</pub-id><pub-id pub-id-type="pmcid">PMC4822297</pub-id></element-citation></ref><ref id="B181-life-12-01440"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dhadda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaplow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>R.Y.K.</given-names></name><name name-style="western"><surname>Lannfelt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer&#8217;s disease with lecanemab, an anti-A&#946; protofibril antibody</article-title><source>Alzheimer&#8217;s Res. Ther.</source><year>2021</year><volume>13</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00813-8</pub-id><pub-id pub-id-type="pmid">33865446</pub-id><pub-id pub-id-type="pmcid">PMC8053280</pub-id></element-citation></ref><ref id="B182-life-12-01440"><label>182.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>A Study to Confirm Safety and Efficacy of Lecanemab in Participants with Early Alzheimer&#8217;s Disease (Clarity AD)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03887455" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03887455</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-18">(accessed on 18 September 2021)</date-in-citation></element-citation></ref><ref id="B183-life-12-01440"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abushouk</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Elmaraezy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aglan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fouda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fouda</surname><given-names>R.</given-names></name><name name-style="western"><surname>AlSafadi</surname><given-names>A.M.</given-names></name></person-group><article-title>Bapineuzumab for mild to moderate Alzheimer&#8217;s disease: A meta-analysis of randomized controlled trials</article-title><source>BMC Neurol.</source><year>2017</year><volume>17</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-017-0850-1</pub-id><pub-id pub-id-type="pmid">28376794</pub-id><pub-id pub-id-type="pmcid">PMC5381133</pub-id></element-citation></ref><ref id="B184-life-12-01440"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Frisardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>D&#8217;Onofrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pietrarossa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Seripa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pilotto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Solfrizzi</surname><given-names>V.</given-names></name></person-group><article-title>Bapineuzumab: Anti-&#946;-amyloid monoclonal antibodies for the treatment of Alzheimer&#8217;s disease</article-title><source>Immunotherapy</source><year>2010</year><volume>2</volume><fpage>767</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.2217/imt.10.80</pub-id><pub-id pub-id-type="pmid">21091109</pub-id></element-citation></ref><ref id="B185-life-12-01440"><label>185.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>Safety and Efficacy Study of Gantenerumab in Participants with Early Alzheimer&#8217;s Disease (AD)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03443973" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT03443973</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-18">(accessed on 18 September 2021)</date-in-citation></element-citation></ref><ref id="B186-life-12-01440"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doggrell</surname><given-names>S.A.</given-names></name></person-group><article-title>Grasping at straws: The failure of solanezumab to modify mild Alzheimer&#8217;s disease</article-title><source>Expert. Opin. Biol. Ther.</source><year>2018</year><volume>18</volume><fpage>1189</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1080/14712598.2018.1543397</pub-id><pub-id pub-id-type="pmid">30376649</pub-id></element-citation></ref><ref id="B187-life-12-01440"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borrie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hager</surname><given-names>K.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Scarpini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu-Seifert</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Trial of Solanezumab for Mild Dementia Due to Alzheimer&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1705971</pub-id><pub-id pub-id-type="pmid">29365294</pub-id></element-citation></ref><ref id="B188-life-12-01440"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Alzheimer disease and aducanumab: Adjusting our approach</article-title><source>Nat. Rev. Neurol.</source><year>2019</year><volume>15</volume><fpage>365</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0205-1</pub-id><pub-id pub-id-type="pmid">31138932</pub-id></element-citation></ref><ref id="B189-life-12-01440"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maciejko</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smalley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>A.</given-names></name></person-group><article-title>Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches</article-title><source>J. Mol. Biomark. Diagn.</source><year>2017</year><volume>8</volume><fpage>350</fpage><pub-id pub-id-type="doi">10.4172/2155-9929.1000350</pub-id><pub-id pub-id-type="pmid">29285416</pub-id><pub-id pub-id-type="pmcid">PMC5743227</pub-id></element-citation></ref><ref id="B190-life-12-01440"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D.</given-names></name></person-group><article-title>Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><fpage>420</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00420</pub-id><pub-id pub-id-type="pmid">32390828</pub-id><pub-id pub-id-type="pmcid">PMC7188913</pub-id></element-citation></ref><ref id="B191-life-12-01440"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoumpourlis</surname><given-names>V.</given-names></name></person-group><article-title>Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13020173</pub-id><pub-id pub-id-type="pmid">33419051</pub-id><pub-id pub-id-type="pmcid">PMC7825410</pub-id></element-citation></ref><ref id="B192-life-12-01440"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Katzman</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeTeresa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pay</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klauber</surname><given-names>M.</given-names></name></person-group><article-title>The Lewy body variant of Alzheimer&#8217;s disease: A clinical and pathologic entity</article-title><source>Neurology</source><year>1990</year><volume>40</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.40.1.1</pub-id><pub-id pub-id-type="pmid">2153271</pub-id></element-citation></ref><ref id="B193-life-12-01440"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rom&#225;n</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>S.J.</given-names></name></person-group><article-title>Donepezil: A clinical review of current and emerging indications</article-title><source>Expert. Opin. Pharmacother.</source><year>2004</year><volume>5</volume><fpage>161</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1517/14656566.5.1.161</pub-id><pub-id pub-id-type="pmid">14680445</pub-id></element-citation></ref><ref id="B194-life-12-01440"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jim&#233;nez Caballero</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Alfonso</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Adalid</surname><given-names>M.</given-names></name></person-group><article-title>Current treatments of Alzheimer disease: Are main caregivers satisfied with the drug treatments received by their patients?</article-title><source>Dement Geriatr. Cogn. Disord.</source><year>2009</year><volume>28</volume><fpage>196</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1159/000236015</pub-id><pub-id pub-id-type="pmid">19738386</pub-id></element-citation></ref><ref id="B195-life-12-01440"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>J.</given-names></name></person-group><article-title>Personalized medicine could transform healthcare</article-title><source>Biomed. Rep.</source><year>2017</year><volume>7</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3892/br.2017.922</pub-id><pub-id pub-id-type="pmid">28685051</pub-id><pub-id pub-id-type="pmcid">PMC5492710</pub-id></element-citation></ref><ref id="B196-life-12-01440"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barman</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nain</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barman</surname><given-names>S.K.</given-names></name></person-group><article-title>CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer&#8217;s Disease-A Narrative Review</article-title><source>Neurol. Ther.</source><year>2020</year><volume>9</volume><fpage>419</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s40120-020-00218-z</pub-id><pub-id pub-id-type="pmid">33089409</pub-id><pub-id pub-id-type="pmcid">PMC7606404</pub-id></element-citation></ref><ref id="B197-life-12-01440"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanisevic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.</given-names></name></person-group><article-title>Metabolomics as a Tool to Understand Pathophysiological Processes</article-title><source>Methods Mol. Biol.</source><year>2018</year><volume>1730</volume><fpage>3</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7592-1_1</pub-id><pub-id pub-id-type="pmid">29363062</pub-id></element-citation></ref><ref id="B198-life-12-01440"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Langbaum</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Caselli</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ayutyanont</surname><given-names>N.</given-names></name><name name-style="western"><surname>Quiroz</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kosik</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lopera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tariot</surname><given-names>P.N.</given-names></name></person-group><article-title>Alzheimer&#8217;s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2011</year><volume>26</volume><issue>(Suppl. 3)</issue><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.3233/JAD-2011-0059</pub-id><pub-id pub-id-type="pmid">21971471</pub-id><pub-id pub-id-type="pmcid">PMC3343739</pub-id></element-citation></ref><ref id="B199-life-12-01440"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mallmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Santacruz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fuqua</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carril</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Althage</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Belyew</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial</article-title><source>Rev. Neurol.</source><year>2013</year><volume>169</volume><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/j.neurol.2013.07.017</pub-id><pub-id pub-id-type="pmid">24016464</pub-id><pub-id pub-id-type="pmcid">PMC3880800</pub-id></element-citation></ref><ref id="B200-life-12-01440"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Karlawish</surname><given-names>J.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name></person-group><article-title>The A4 study: Stopping AD before symptoms begin?</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>228fs213</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007941</pub-id><pub-id pub-id-type="pmcid">PMC4049292</pub-id><pub-id pub-id-type="pmid">24648338</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="life-12-01440-f001" orientation="portrait"><label>Figure 1</label><caption><p>APP amyloidogenic and non-amyloidogenic processing pathways. In the nonamyloidogenic pathway, APP is cleaved by &#945;-secretase to produce a soluble amino-terminal of the amyloid precursor protein, as well as a C-terminal fragment (C83) that can subsequently be cleaved by &#947;-secretase to produce the p3 extracellular fragment and amyloid precursor protein intracellular domain (AICD). In the amyloidogenic pathway, &#946;-secretase cleaves APP to generate the soluble amyloid precursor protein &#946;- and a C-terminal fragment (C99). Then, the cleavage of C99 by &#947;-secretase leads to the release of amyloid-&#946; and AICD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="life-12-01440-g001.jpg"/></fig><fig position="float" id="life-12-01440-f002" orientation="portrait"><label>Figure 2</label><caption><p>Possible mechanisms of anti-A&#946; antibodies. Passive immunotherapies directly supply antibodies to the host and anti-A&#946; antibodies interfere with the &#946;-amyloid cascade at various levels. (<bold>A</bold>) Blocking of oligomer formation. (<bold>B</bold>) Plaque phagocytosis by microglia (Fc-mediated phagocytosis). (<bold>C</bold>) Direct mechanism of action towards A&#946; plaques via antibody-mediated disassembly. (<bold>D</bold>) Slowing and halting of fibril elongation. (<bold>E</bold>) The refuted peripheral sink mechanism (monomer efflux from CNS) and shift in concentration gradient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="life-12-01440-g002.jpg"/></fig></floats-group></article></pmc-articleset>